id category authors creation_date issue published_in summary volume PMID:13679426 biolink:Article|biolink:NamedThing|biolink:Publication Chen M, Dong Y, Simard JM 2003 24 J Neurosci Functional coupling between sulfonylurea receptor type 1 and a nonselective cation channel in reactive astrocytes from adult rat brain 23 PMID:10064839 biolink:Article|biolink:NamedThing|biolink:Publication Chou YC, Liao JF, Chang WY, Lin MF, Chen CF 1999 2 Brain Res Binding of dimemorfan to sigma-1 receptor and its anticonvulsant and locomotor effects in mice, compared with dextromethorphan and dextrorphan 821 PMID:21818695 biolink:Article|biolink:NamedThing|biolink:Publication Benet LZ, Broccatelli F, Oprea TI 2011 4 The AAPS journal BDDCS applied to over 900 drugs 13 PMID:15546675 biolink:Article|biolink:NamedThing|biolink:Publication Contrera JF, Matthews EJ, Kruhlak NL, Benz RD 2004 3 Regul Toxicol Pharmacol Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose 40 PMID:26589308 biolink:Article|biolink:NamedThing|biolink:Publication Hosey CM, Chan R, Benet LZ 2016 1 The AAPS journal BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs 18 PMID:24306326 biolink:Article|biolink:NamedThing|biolink:Publication Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H 2014 4 Pharm Res Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches 31 PMID:30115648 biolink:Article|biolink:NamedThing|biolink:Publication Lombardo F, Berellini G, Obach RS 2018 11 Drug Metab Dispos Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds 46 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761115Orig1s000MultidisciplineR.pdf biolink:NamedThing|biolink:Publication 2020 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf biolink:NamedThing|biolink:Publication 2020 PMID:21918175 biolink:Article|biolink:NamedThing|biolink:Publication Liu X, Wang Q, Yang G, Marando C, Koblish HK, Hall LM, Fridman JS, Behshad E, Wynn R, Li Y, Boer J, Diamond S, He C, Xu M, Zhuo J, Yao W, Newton RC, Scherle PA 2011 22 Clin Cancer Res A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3 17 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf biolink:NamedThing|biolink:Publication 2020 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213246Orig1s000MultidisciplineR.pdf biolink:NamedThing|biolink:Publication 2020 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213973s000lbl.pdf biolink:NamedThing|biolink:Publication 2020 PMID:31085175 biolink:Article|biolink:NamedThing|biolink:Publication Smith BD, Kaufman MD, Lu WP, Gupta A, Leary CB, Wise SC, Rutkoski TJ, Ahn YM, Al-Ani G, Bulfer SL, Caldwell TM, Chun L, Ensinger CL, Hood MM, McKinley A, Patt WC, Ruiz-Soto R, Su Y, Telikepalli H, Town A, Turner BA, Vogeti L, Vogeti S, Yates K, Janku F, Abdul Razak AR, Rosen O, Heinrich MC, Flynn DL 2019 5 Cancer Cell Ripretinib (DCC-2618) is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA variants 35 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212155s000lbl.pdf biolink:NamedThing|biolink:Publication 2020 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212123s000lbl.pdf biolink:NamedThing|biolink:Publication 2020 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761142s000lbl.pdf biolink:NamedThing|biolink:Publication 2020 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf biolink:NamedThing|biolink:Publication 2020 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212295s000lbl.pdf biolink:NamedThing|biolink:Publication 2020 PMID:17585216 biolink:Article|biolink:NamedThing|biolink:Publication Kilpatrick GJ, McIntyre MS, Cox RF, Stafford JA, Pacofsky GJ, Lovell GG, Wiard RP, Feldman PL, Collins H, Waszczak BL, Tilbrook GS 2007 1 Anesthesiology CNS 7056: a novel ultra-short-acting benzodiazepine 107 PMID:22547625 biolink:Article|biolink:NamedThing|biolink:Publication Nowicka-Sans B, Gong YF, McAuliffe B, Dicker I, Ho HT, Zhou N, Eggers B, Lin PF, Ray N, Wind-Rotolo M, Zhu L, Majumdar A, Stock D, Lataillade M, Hanna GJ, Matiskella JD, Ueda Y, Wang T, Kadow JF, Meanwell NA, Krystal M 2012 7 Antimicrob Agents Chemother In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068 56 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf biolink:NamedThing|biolink:Publication 2020 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212576s000lbl.pdf biolink:NamedThing|biolink:Publication 2020 PMID:24520856 biolink:Article|biolink:NamedThing|biolink:Publication Ferraris D, Duvall B, Delahanty G, Mistry B, Alt J, Rojas C, Rowbottom C, Sanders K, Schuck E, Huang KC, Redkar S, Slusher BB, Tsukamoto T 2014 6 J Med Chem Design, synthesis, and pharmacological evaluation of fluorinated tetrahydrouridine derivatives as inhibitors of cytidine deaminase 57 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761163Orig1s000MultidisciplineR.pdf biolink:NamedThing|biolink:Publication 2020 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761163s000lbl.pdf biolink:NamedThing|biolink:Publication 2020 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761158Orig1s000MultidisciplineR.pdf biolink:NamedThing|biolink:Publication 2020 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761158s000lbl.pdf biolink:NamedThing|biolink:Publication 2020 PMID:32936437 biolink:Article|biolink:NamedThing|biolink:Publication Markham A 2020 15 Drugs Belantamab Mafodotin: First Approval 80 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210730s000lbl.pdf biolink:NamedThing|biolink:Publication 2020 PMID:23300227 biolink:Article|biolink:NamedThing|biolink:Publication DeWire SM, Yamashita DS, Rominger DH, Liu G, Cowan CL, Graczyk TM, Chen XT, Pitis PM, Gotchev D, Yuan C, Koblish M, Lark MW, Violin JD 2013 3 J Pharmacol Exp Ther A G protein-biased ligand at the mu-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine 344 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212154Orig1s000lbl.pdf biolink:NamedThing|biolink:Publication 2020 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212154Orig1s000PharmR.pdf biolink:NamedThing|biolink:Publication 2020 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761149s000lbl.pdf biolink:NamedThing|biolink:Publication 2020 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761149Orig1s000PharmR.pdf biolink:NamedThing|biolink:Publication 2020 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213433s000lbl.pdf biolink:NamedThing|biolink:Publication 2020 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213227s000lbl.pdf biolink:NamedThing|biolink:Publication 2020 PMID:29668724 biolink:Article|biolink:NamedThing|biolink:Publication Rylova SN, Stoykow C, Del Pozzo L, Abiraj K, Tamma ML, Kiefer Y, Fani M, Maecke HR 2018 4 PLoS One The somatostatin receptor 2 antagonist 64Cu-NODAGA-JR11 outperforms 64Cu-DOTA-TATE in a mouse xenograft mod 13 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213721s000lbl.pdf biolink:NamedThing|biolink:Publication 2020 PMID:29657135 biolink:Article|biolink:NamedThing|biolink:Publication Subbiah V, Gainor JF, Rahal R, Brubaker JD, Kim JL, Maynard M, Hu W, Cao Q, Sheets MP, Wilson D, Wilson KJ, DiPietro L, Fleming P, Palmer M, Hu MI, Wirth L, Brose MS, Ou SI, Taylor M, Garralda E, Miller S, Wolf B, Lengauer C, Guzi T, Evans EK 2018 7 Cancer Discov Precision targeted therapy with BLU-667 for RET-driven cancers 8 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214787Orig1s000lbl.pdf biolink:NamedThing|biolink:Publication 2020 PMID:32668216 biolink:Article|biolink:NamedThing|biolink:Publication Pruijssers AJ, George AS, Schafer A, Leist SR, Gralinksi LE, Dinnon KH 3rd, Yount BL, Agostini ML, Stevens LJ, Chappell JD, Lu X, Hughes TM, Gully K, Martinez DR, Brown AJ, Graham RL, Perry JK, Du Pont V, Pitts J, Ma B, Babusis D, Murakami E, Feng JY, Bilello JP, Porter DP, Cihlar T, Baric RS, Denison MR, Sheahan TP 2020 3 Cell Rep Remdesivir inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice 32 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761156s000lbl.pdf biolink:NamedThing|biolink:Publication 2020 PMID:32053994 biolink:Article|biolink:NamedThing|biolink:Publication Petersen M, Gandhi PS, Buchardt J, Alanentalo T, Fels JJ, Johansen NL, Helding-Kvist P, Vad K, Thygesen P 2020 4 Int J Mol Sci Tissue distribution and receptor activation by somapacitan, a long acting growth hormone derivative 21 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213969s000lbl.pdf biolink:NamedThing|biolink:Publication 2020 PMID:10377218 biolink:Article|biolink:NamedThing|biolink:Publication Strickland CL, Weber PC, Windsor WT, Wu Z, Le HV, Albanese MM, Alvarez CS, Cesarz D, del Rosario J, Deskus J, Mallams AK, Njoroge FG, Piwinski JJ, Remiszewski S, Rossman RR, Taveras AG, Vibulbhan B, Doll RJ, Girijavallabhan VM, Ganguly AK 1999 12 J Med Chem Tricyclic farnesyl protein transferase inhibitors: crystallographic and calorimetric studies of structure−activity relationships 42 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213793Orig1s000RPLlbl.pdf biolink:NamedThing|biolink:Publication 2020 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213793Orig1s000ClinPharmR.pdf biolink:NamedThing|biolink:Publication 2020 https://www.ema.europa.eu/en/documents/product-information/hepcludex-epar-product-information_en.pdf biolink:NamedThing|biolink:Publication 2020 PMID:33058042 biolink:Article|biolink:NamedThing|biolink:Publication Al-Salama ZT 2020 17 Drugs Imlifidase: first approval 80 https://www.ema.europa.eu/en/documents/product-information/jyseleca-epar-product-information_en.pdf biolink:NamedThing|biolink:Publication 2020 PMID:24006460 biolink:Article|biolink:NamedThing|biolink:Publication Van Rompaey L, Galien R, van der Aar EM, Clement-Lacroix P, Nelles L, Smets B, Lepescheux L, Christophe T, Conrath K, Vandeghinste N, Vayssiere B, De Vos S, Fletcher S, Brys R, van't Klooster G, Feyen JH, Menet C 2013 7 J Immunol Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases 191 PMID:32852744 biolink:Article|biolink:NamedThing|biolink:Publication Markham A 2020 13 Drugs Vadadustat: first approval 80 PMID:32880805 biolink:Article|biolink:NamedThing|biolink:Publication Dhillon S 2020 14 Drugs Daprodustat: first approval 80 PMID:28928122 biolink:Article|biolink:NamedThing|biolink:Publication Ariazi JL, Duffy KJ, Adams DF, Fitch DM, Luo L, Pappalardi M, Biju M, DiFilippo EH, Shaw T, Wiggall K, Erickson-Miller C 2017 3 J Pharmacol Exp Ther Discovery and preclinical characterization of GSK1278863 (daprodustat), a small molecule hypoxia inducible factor-prolyl hydroxylase inhibitor for anemia 363 PMID:31953125 biolink:Article|biolink:NamedThing|biolink:Publication Liclican A, Serafini L, Xing W, Czerwieniec G, Steiner B, Wang T, Brendza KM, Lutz JD, Keegan KS, Ray AS, Schultz BE, Sakowicz R, Feng JY 2020 4 Biochim Biophys Acta Gen Subj Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition 1864 PMID:32361823 biolink:Article|biolink:NamedThing|biolink:Publication Markham A 2020 8 Drugs Tepotinib: first approval 80 PMID:23553846 biolink:Article|biolink:NamedThing|biolink:Publication Bladt F, Faden B, Friese-Hamim M, Knuehl C, Wilm C, Fittschen C, Gradler U, Meyring M, Dorsch D, Jaehrling F, Pehl U, Stieber F, Schadt O, Blaukat A 2013 11 Clin Cancer Res EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors 19 PMID:31371478 biolink:Article|biolink:NamedThing|biolink:Publication Taniguchi T, Ashizawa N, Matsumoto K, Saito R, Motoki K, Sakai M, Chikamatsu N, Hagihara C, Hashiba M, Iwanaga T 2019 1 J Pharmacol Exp Ther Pharmacological evaluation of dotinurad, a selective urate reabsorption inhibitor 371 PMID:33062187 biolink:Article|biolink:NamedThing|biolink:Publication Uda J, Kobashi S, Miyata S, Ashizawa N, Matsumoto K, Iwanaga T 2020 10 ACS Med Chem Lett Discovery of dotinurad (FYU-981), a new phenol derivative with highly potent uric acid lowering activity 11 PMID:25387665 biolink:Article|biolink:NamedThing|biolink:Publication Tanimoto A, Ogawa Y, Oki C, Kimoto Y, Nozawa K, Amano W, Noji S, Shiozaki M, Matsuo A, Shinozaki Y, Matsushita M 2015 1 Inflamm Res Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo 64 PMID:31301309 biolink:Article|biolink:NamedThing|biolink:Publication Fukui K, Shinozaki Y, Kobayashi H, Deai K, Yoshiuchi H, Matsui T, Matsuo A, Matsushita M, Tanaka T, Nangaku M 2019 859 Eur J Pharmacol JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF-α protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor 15 PMID:33320297 biolink:Article|biolink:NamedThing|biolink:Publication Markham A 2020 Drugs Enarodustat: first approval PMID:33236266 biolink:Article|biolink:NamedThing|biolink:Publication Paik J 2020 18 Drugs Sofpironium Bromide: first approval 80 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212642s000lbl.pdf biolink:NamedThing|biolink:Publication 2020 PMID:29619657 biolink:Article|biolink:NamedThing|biolink:Publication Sanchez-Crespo A, Jussing E, Björklund AC, Pokrovskaja Tamm K 2018 1 EJNMMI Res Hallmarks in prostate cancer imaging with Ga68-PSMA-11-PET/CT with reference to detection limits and quantitative properties 8 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214094s000lbl.pdf biolink:NamedThing|biolink:Publication 2020 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214094Orig1s000MultidisciplineR.pdf biolink:NamedThing|biolink:Publication 2020 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214621s000lbl.pdf biolink:NamedThing|biolink:Publication 2020 PMID:30937733 biolink:Article|biolink:NamedThing|biolink:Publication Markham A 2019 6 Drugs Relugolix: first global approval 79 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761172s000lbl.pdf biolink:NamedThing|biolink:Publication 2020 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf biolink:NamedThing|biolink:Publication 2020 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761171lbl.pdf biolink:NamedThing|biolink:Publication 2020 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761171Orig1s000MultidisciplineR.pdf biolink:NamedThing|biolink:Publication 2020 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761169s000lbl.pdf biolink:NamedThing|biolink:Publication 2020 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213973Orig1s000MultidisciplineR.pdf biolink:NamedThing|biolink:Publication 2020 PMID:20605905 biolink:Article|biolink:NamedThing|biolink:Publication Herbst R, Wang Y, Gallagher S, Mittereder N, Kuta E, Damschroder M, Woods R, Rowe DC, Cheng L, Cook K, Evans K, Sims GP, Pfarr DS, Bowen MA, Dall'Acqua W, Shlomchik M, Tedder TF, Kiener P, Jallal B, Wu H, Coyle AJ 2010 1 J Pharmacol Exp Ther B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody 335 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/210730Orig1s000MultidisciplineR.pdf biolink:NamedThing|biolink:Publication 2020 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213433Orig1s000MultidisciplineR.pdf biolink:NamedThing|biolink:Publication 2020 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213721Orig1s000MultidisciplineR.pdf biolink:NamedThing|biolink:Publication 2020 PMID:31132753 biolink:Article|biolink:NamedThing|biolink:Publication Bailly C 2019 Phytomedicine Cepharanthine: An update of its mode of action, pharmacological properties and medical applications 62 PMID:32149769 biolink:Article|biolink:NamedThing|biolink:Publication Fan HH, Wang LQ, Liu WL, An XP, Liu ZD, He XQ, Song LH, Tong YG 2020 Chin Med J Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model DOI:10.26434/chemrxiv.12039888.v1 biolink:Article|biolink:NamedThing|biolink:Publication Xu Z, Yao H, Shen J, Wu N, Xu Y, Lu X 2020 ChemRxiv Nelfinavir is active against SARS-CoV-2 in Vero E6 cells PMID:32251768 biolink:Article|biolink:NamedThing|biolink:Publication Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM 2020 Antiviral Res The FDA-approved drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro DOI:10.1101/2020.03.20.999730 biolink:Article|biolink:NamedThing|biolink:Publication Jeon S, Ko M, Lee J, Choi I, Byun SY, Park S, Shum D, Kim S 2020 bioRxiv Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs DOI:10.1101/2020.04.03.023846 biolink:Article|biolink:NamedThing|biolink:Publication Touret F, Gilles M, Barral K, Nougairede A, Decroly E, de Lamballerie X, Coutard B 2020 bioRxiv In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication PMID:32194981 biolink:Article|biolink:NamedThing|biolink:Publication Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, Li Y, Hu Z, Zhong W, Wang M 2020 16 Cell Discov Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro 6 PMID:32251767 biolink:Article|biolink:NamedThing|biolink:Publication Choy KT, Wong AY, Kaewpreedee P, Sia SF, Chen D, Hui KPY, Chu DKW, Chan MCW, Cheung PP, Huang X, Peiris M, Yen HL 2020 Antiviral Res Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro 178 PMID:32020029 biolink:Article|biolink:NamedThing|biolink:Publication Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G 2020 3 Cell Res Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro 30 DOI:10.1101/2020.03.11.987016 biolink:Article|biolink:NamedThing|biolink:Publication Matsuyama S, Kawase M, Nao N, Shirato K, Ujike M, Kamitani W, Shimojima M, Fukushi S 2020 bioRxiv The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15 DOI:10.1101/2020.03.23.004580 biolink:Article|biolink:NamedThing|biolink:Publication Li Z, Li X, Huang YY, Wu Y, Zhou L, Liu R, Wu D, Zhang L, Liu H, Xu X, Zhang Y, Cui J, Wang X, Luo HB 2020 bioRxiv FEP-based screening prompts drug repositioning against COVID-19 DOI:10.1101/2020.02.05.935387 biolink:Article|biolink:NamedThing|biolink:Publication Zhang J, Ma X, Yu F, Liu J, Zou F, Pan T, Zhang H 2020 bioRxiv Teicoplanin potently blocks the cell entry of 2019-nCoV PMID:32253226 biolink:Article|biolink:NamedThing|biolink:Publication Sheahan TP, Sims AC, Zhou S, Graham RL, Pruijssers AJ, Agostini ML, Leist SR, Schafer A, Dinnon KH, Stevens LJ, Chappell JD, Lu X, Hughes TM, George AS, Hill CS, Montgomery SA, Brown AJ, Bluemling GR, Natchus MG, Saindane M, Kolykhalov AA, Painter G, Harcourt J, Tamin A, Thornburg NJ, Swanstrom R, Denison MR, Baric RS 2020 Sci Transl Med An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice DOI:10.1101/2020.03.11.986836 biolink:Article|biolink:NamedThing|biolink:Publication Ge Y, Tian T, Huang S, Wan F, Li J, Li S, Yang H, Hong L, Wu N, Yuan E, Cheng L, Lei Y, Shu H, Feng X, Jiang Z, Chi Y, Guo X, Cui L, Xiao L, Li Z, Yang C, Miao Z, Tang H, Chen L, Zeng H, Zhao D, Zhu F, Shen X, Zeng J 2020 bioRxiv A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212608s000lbl.pdf biolink:NamedThing|biolink:Publication 2020 PMID:29093181 biolink:Article|biolink:NamedThing|biolink:Publication Evans EK, Gardino AK, Kim JL, Hodous BL, Shutes A, Davis A, Zhu XJ, Schmidt-Kittler O, Wilson D, Wilson K, DiPietro L, Zhang Y, Brooijmans N, LaBranche TP, Wozniak A, Gebreyohannes YK, Schöffski P, Heinrich MC, DeAngelo DJ, Miller S, Wolf B, Kohl N, Guzi T, Lydon N, Boral A, Lengauer C 2017 414 Sci Transl Med A precision therapy against cancers driven by KIT/PDGFRA mutations 9 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211723s000lbl.pdf biolink:NamedThing|biolink:Publication 2020 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212728s000lbl.pdf biolink:NamedThing|biolink:Publication 2020 PMID:23153230 biolink:Article|biolink:NamedThing|biolink:Publication Luo G, Chen L, Conway CM, Denton R, Keavy D, Signor L, Kostich W, Lentz KA, Santone KS, Schartman R, Browning M, Tong G, Houston JG, Dubowchik GM, Macor JE 2012 23 J Med Chem Discovery of (5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate (BMS-927711): an oral calcitonin gene-related peptide (CGRP) antagonist in clinical trials for treating migraine 55 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211616s000lbl.pdf biolink:NamedThing|biolink:Publication 2020 PMID:27892461 biolink:Article|biolink:NamedThing|biolink:Publication Pinkosky SL, Newton RS, Day EA, Ford RJ, Lhotak S, Austin RC, Birch CM, Smith BK, Filippov S, Groot PHE, Steinberg GR, Lalwani ND 2016 Nat Commun Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis 7 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209899s000lbl.pdf biolink:NamedThing|biolink:Publication 2020 PMID:26990079 biolink:Article|biolink:NamedThing|biolink:Publication Scott FL, Clemons B, Brooks J, Brahmachary E, Powell R, Dedman H, Desale HG, Timony GA, Martinborough E, Rosen H, Roberts E, Boehm MF, Peach RJ 2016 11 Br J Pharmacol Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity 173 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212801s000lbl.pdf biolink:NamedThing|biolink:Publication 2020 PMID:32141023 biolink:Article|biolink:NamedThing|biolink:Publication Duggan S 2020 5 Drugs Osilodrostat: First Approval 80 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761113s000lbl.pdf biolink:NamedThing|biolink:Publication 2020 PMID:24987056 biolink:Article|biolink:NamedThing|biolink:Publication Deckert J, Wetzel MC, Bartle LM, Skaletskaya A, Goldmacher VS, Vallee F, Zhou-Liu Q, Ferrari P, Pouzieux S, Lahoute C, Dumontet C, Plesa A, Chiron M, Lejeune P, Chittenden T, Park PU, Blanc V 2014 17 Clin Cancer Res SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies 20 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761119s000lbl.pdf biolink:NamedThing|biolink:Publication 2020 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761119Orig1s000OtherR.pdf biolink:NamedThing|biolink:Publication 2020 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761143s000lbl.pdf biolink:NamedThing|biolink:Publication 2020 PMID:20847162 biolink:Article|biolink:NamedThing|biolink:Publication Heskamp S, van Laarhoven HW, Molkenboer-Kuenen JD, Franssen GM, Versleijen-Jonkers YM, Oyen WJ, van der Graaf WT, Boerman OC 2010 10 J Nucl Med ImmunoSPECT and immunoPET of IGF-1R expression with the radiolabeled antibody R1507 in a triple-negative breast cancer model 51 PMID:17332304 biolink:Article|biolink:NamedThing|biolink:Publication Yeh TC, Marsh V, Bernat BA, Ballard J, Colwell H, Evans RJ, Parry J, Smith D, Brandhuber BJ, Gross S, Marlow A, Hurley B, Lyssikatos J, Lee PA, Winkler JD, Koch K, Wallace E 2007 5 Clin Cancer Res Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor 13 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000lbl.pdf biolink:NamedThing|biolink:Publication 2020 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213411s000lbl.pdf biolink:NamedThing|biolink:Publication 2020 PMID:32241871 biolink:Article|biolink:NamedThing|biolink:Publication Kulukian A, Lee P, Taylor J, Rosler R, de Vries P, Watson D, Forero-Torres A, Peterson S 2020 4 Mol Cancer Ther Preclinical activity of HER2-Selective tyrosine kinase inhibitor tucatinib as a single agent or in combination with trastuzumab or docetaxel in solid tumor models 19 PMID:32315352 biolink:Article|biolink:NamedThing|biolink:Publication Liu PCC, Koblish H, Wu L, Bowman K, Diamond S, DiMatteo D, Zhang Y, Hansbury M, Rupar M, Wen X, Collier P, Feldman P, Klabe R, Burke KA, Soloviev M, Gardiner C, He X, Volgina A, Covington M, Ruggeri B, Wynn R, Burn TC, Scherle P, Yeleswaram S, Yao W, Huber R, Hollis G 2020 4 PLoS One INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models 15 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf biolink:NamedThing|biolink:Publication 2020 PMID:27926532 biolink:Article|biolink:NamedThing|biolink:Publication He JX, Wang M, Huan XJ, Chen CH, Song SS, Wang YQ, Liao XM, Tan C, He Q, Tong LJ, Wang YT, Li XH, Su Y, Shen YY, Sun YM, Yang XY, Chen Y, Gao ZW, Chen XY, Xiong B, Lu XL, Ding J, Yang CH, Miao ZH 2017 3 Oncotarget Novel PARP1/2 inhibitor mefuparib hydrochloride elicits potent in vitro and in vivo anticancer activity, characteristic of high tissue distribution 8 PMID:26934220 biolink:Article|biolink:NamedThing|biolink:Publication Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, Siegel D, Perron M, Bannister R, Hui HC, Larson N, Strickley R, Wells J, Stuthman KS, Van Tongeren SA, Garza NL, Donnelly G, Shurtleff AC, Retterer CJ, Gharaibeh D, Zamani R, Kenny T, Eaton BP, Grimes E, Welch LS, Gomba L, Wilhelmsen CL, Nichols DK, Nuss JE, Nagle ER, Kugelman JR, Palacios G, Doerffler E, Neville S, Carra E, Clarke MO, Zhang L, Lew W, Ross B, Wang Q, Chun K, Wolfe L, Babusis D, Park Y, Stray KM, Trancheva I, Feng JY, Barauskas O, Xu Y, Wong P, Braun MR5, Flint M, McMullan LK, Chen SS, Fearns R5, Swaminathan S, Mayers DL, Spiropoulou CF, Lee WA, Nichol ST, Cihlar T, Bavari S 2016 7594 Nature Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys 531 DOI:10.1016/S0016-5085(10)61017-7 biolink:Article|biolink:NamedThing|biolink:Publication Gillberg, Per-Göran; Dahlström, Mikael; AU - Starke, Ingemar; Östlund-Lindqvist, Ann-Margret 2010 5 Gastroenterology S1301 The IBAT Inhibition by A3309 - A Potential Mechanism for the Treatment of Constipation 138 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210491lbl.pdf biolink:NamedThing|biolink:Publication 2018 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208700s000lbl.pdf biolink:NamedThing|biolink:Publication 2018 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205598s000lbl.pdf biolink:NamedThing|biolink:Publication 2017 PMID:12240910 biolink:Article|biolink:NamedThing|biolink:Publication Broglio F, Boutignon F, Benso A, Gottero C, Prodam F, Arvat E, Ghè C, Catapano F, Torsello A, Locatelli V, Muccioli G, Boeglin D, Guerlavais V, Fehrentz JA, Martinez J, Ghigo E, Deghenghi R 2002 8 J. Endocrinol. Invest. EP1572: a novel peptido-mimetic GH secretagogue with potent and selective GH-releasing activity in man. 25 PMID:24002361 biolink:Article|biolink:NamedThing|biolink:Publication Butler MS, Blaskovich MA, Cooper MA 2013 10 J Antibiot (Tokyo) Antibiotics in the clinical pipeline in 2013 66 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761092s000lbl.pdf biolink:NamedThing|biolink:Publication 2018 PMID:27645238 biolink:Article|biolink:NamedThing|biolink:Publication Tsiang M, Jones GS, Goldsmith J, Mulato A, Hansen D, Kan E, Tsai L, Bam RA, Stepan G, Stray KM, Niedziela-Majka A, Yant SR, Yu H, Kukolj G, Cihlar T, Lazerwith SE, White KL, Jin H 2016 12 Antimicrob. Agents Chemother. Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile. 60 PMID:16135657 biolink:Article|biolink:NamedThing|biolink:Publication Iwanaga T, Kobayashi D, Hirayama M, Maeda T, Tamai I 2005 12 Drug Metab. Dispos. Involvement of uric acid transporter in increased renal clearance of the xanthine oxidase inhibitor oxypurinol induced by a uricosuric agent, benzbromarone. 33 https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/021462lbl.pdf biolink:NamedThing|biolink:Publication 2004 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761065s001lbl.pdf biolink:NamedThing|biolink:Publication 2018 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209299lbl.pdf biolink:NamedThing|biolink:Publication 2018 PMID:16946104 biolink:Article|biolink:NamedThing|biolink:Publication Braselmann S, Taylor V, Zhao H, Wang S, Sylvain C, Baluom M, Qu K, Herlaar E, Lau A, Young C, Wong BR, Lovell S, Sun T, Park G, Argade A, Jurcevic S, Pine P, Singh R, Grossbard EB, Payan DG, Masuda ES. 2006 3 J Pharmacol Exp Ther. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. 319 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761067s000lbl.pdf biolink:NamedThing|biolink:Publication 2018 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761068s000lbl.pdf biolink:NamedThing|biolink:Publication 2018 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210493s000lbl.pdf/drugsatfda_docs/label/2014/125477s007lbl.pdf biolink:NamedThing|biolink:Publication 2018 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761077s000lbl.pdf biolink:NamedThing|biolink:Publication 2018 PMID:19183407 biolink:Article|biolink:NamedThing|biolink:Publication Fukushima-Shintani M, Suzuki K, Iwatsuki Y, Abe M, Sugasawa K, Hirayama F, Kawasaki T, Nakahata T 2009 4 Eur. J. Haematol. AKR-501 (YM477) a novel orally-active thrombopoietin receptor agonist. 82 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf biolink:NamedThing|biolink:Publication 2018 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210496lbl.pdf biolink:NamedThing|biolink:Publication 2018 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210498lbl.pdf biolink:NamedThing|biolink:Publication 2018 PMID:26559125 biolink:Article|biolink:NamedThing|biolink:Publication Shi L, Lehto SG, Zhu DX, Sun H, Zhang J, Smith BP, Immke DC, Wild KD, Xu C 2016 1 J. Pharmacol. Exp. Ther. Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide Receptor. 356 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208627s000lbl.pdf biolink:NamedThing|biolink:Publication 2018 PMID:29670690 biolink:Article|biolink:NamedThing|biolink:Publication Popovici-Muller J, Lemieux RM, Artin E, Saunders JO, Salituro FG, Travins J, Cianchetta G, Cai Z, Zhou D, Cui D, Chen P, Straley K, Tobin E, Wang F, David MD, Penard-Lacronique V, Quivoron C, Saada V, de Botton S, Gross S, Dang L, Yang H, Utley L, Chen Y, Kim H, Jin S, Gu Z, Yao G, Luo Z, Lv X, Fang C, Yan L, Olaharski A, Silverman L, Biller S, Su SM, Yen K. 2018 4 ACS Med. Chem. Lett. Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers 9 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211192s000lbl.pdf biolink:NamedThing|biolink:Publication 2018 PMID:19006286 biolink:Article|biolink:NamedThing|biolink:Publication Chen C, Wu D, Guo Z, Xie Q, Reinhart GJ, Madan A, Wen J, Chen T, Huang CQ, Chen M, Chen Y, Tucci FC, Rowbottom M, Pontillo J, Zhu YF, Wade W, Saunders J, Bozigian H, Struthers RS 2008 23 J. Med. Chem. Discovery of Sodium R-(+)-4-{2-[5-(2-Fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (Elagolix), a Potent and Orally Available Nonpeptide Antagonist of the Human Gonadotropin-Releasing Hormone Receptor 51 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210450s000lbl.pdf biolink:NamedThing|biolink:Publication 2018 PMID:29274361 biolink:Article|biolink:NamedThing|biolink:Publication Yoshida H, Yamada H, Nogami W, Dohi K, Kurino-Yamada T, Sugiyama K, Takahashi K, Gahara Y, Kitaura M, Hasegawa M, Oshima I, Kuwabara K. 2018 Exp. Hematol. Development of a new knock-in mouse model and evaluation of pharmacological activities of lusutrombopag, a novel, nonpeptidyl small-molecule agonist of the human thrombopoietin receptor c-Mpl 59 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211109lbl.pdf biolink:NamedThing|biolink:Publication 2018 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf biolink:NamedThing|biolink:Publication 2018 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211155s000lbl.pdf biolink:NamedThing|biolink:Publication 2018 PMID:24211136 biolink:Article|biolink:NamedThing|biolink:Publication Winkler DG, Faia KL, DiNitto JP, Ali JA, White KF, Brophy EE, Pink MM, Proctor JL, Lussier J, Martin CM, Hoyt JG, Tillotson B, Murphy EL, Lim AR, Thomas BD, Macdougall JR, Ren P, Liu Y, Li LS, Jessen KA, Fritz CC, Dunbar JL, Porter JR, Rommel C, Palombella VJ, Changelian PS, Kutok JL 2013 11 Chem. Biol. PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. 20 PMID:30506139 biolink:Article|biolink:NamedThing|biolink:Publication Shirley M 2018 18 Drugs Dacomitinib: First Global Approval. 78 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf biolink:NamedThing|biolink:Publication 2018 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209816_209817lbl.pdf biolink:NamedThing|biolink:Publication 2018 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211651s000lbl.pdf biolink:NamedThing|biolink:Publication 2018 PMID:26652717 biolink:Article|biolink:NamedThing|biolink:Publication Wang B, Chu D, Feng Y, Shen Y, Aoyagi-Scharber M, Post LE 2016 1 J. Med. Chem. Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent. 59 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210868s000lbl.pdf biolink:NamedThing|biolink:Publication 2018 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761102s000lbl.pdf biolink:NamedThing|biolink:Publication 2018 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210910s000lbl.pdf biolink:NamedThing|biolink:Publication 2018 PMID:26144315 biolink:Article|biolink:NamedThing|biolink:Publication Zou HY, Friboulet L, Kodack DP, Engstrom LD, Li Q, West M, Tang RW, Wang H, Tsaparikos K, Wang J, Timofeevski S, Katayama R, Dinh DM, Lam H, Lam JL, Yamazaki S, Hu W, Patel B, Bezwada D, Frias RL, Lifshits E, Mahmood S, Gainor JF, Affolter T, Lappin PB, Gukasyan H, Lee N, Deng S, Jain RK, Johnson TW, Shaw AT, Fantin VR, Smeal T. 2015 1 Cancer Cell. PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models. 28 PMID:27401242 biolink:Article|biolink:NamedThing|biolink:Publication Facchinetti F, Loriot Y, Kuo MS, Mahjoubi L, Lacroix L, Planchard D, Besse B, Farace F, Auger N, Remon J, Scoazec JY, Andre F, Soria JC, Friboulet L 2016 24 Clin. Cancer. Res. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers. 22 PMID:25733882 biolink:Article|biolink:NamedThing|biolink:Publication Zou HY, Li Q, Engstrom LD, West M, Appleman V, Wong KA, McTigue M, Deng YL, Liu W, Brooun A, Timofeevski S, McDonnell SR, Jiang P, Falk MD, Lappin PB, Affolter T, Nichols T, Hu W, Lam J, Johnson TW, Smeal T, Charest A, Fantin VR 2015 11 Proc. Natl. Acad. Sci. USA PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations. 112 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210598s000lbl.pdf biolink:NamedThing|biolink:Publication 2018 PMID:29736245 biolink:Article|biolink:NamedThing|biolink:Publication Hegde SS, Pulido-Rios MT, Luttmann MA, Foley JJ, Hunsberger GE, Steinfeld T, Lee T, Ji Y, Mammen MM, Jasper JR 2018 3 Pharmacol. Res. Perspect. Pharmacological properties of revefenacin (TD-4208), a novel, nebulized long-acting, and lung selective muscarinic antagonist, at human recombinant muscarinic receptors and in rat, guinea pig, and human isolated airway tissues. 6 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210656s000lbl.pdf biolink:NamedThing|biolink:Publication 2018 PMID:24900436 biolink:Article|biolink:NamedThing|biolink:Publication Munchhof MJ, Li Q, Shavnya A, Borzillo GV, Boyden TL, Jones CS, LaGreca SD, Martinez-Alsina L, Patel N, Pelletier K, Reiter LA, Robbins MD, Tkalcevic GT 2011 2 ACS Med. Chem. Lett. Discovery of PF-04449913, a Potent and Orally Bioavailable Inhibitor of Smoothened. 3 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf biolink:NamedThing|biolink:Publication 2018 PMID:21138586 biolink:Article|biolink:NamedThing|biolink:Publication Ghilardi JR, Freeman KT, Jimenez-Andrade JM, Mantyh WG, Bloom AP, Kuskowski MA, Mantyh PW. 2010 1 Mol. Pain Administration of a tropomyosin receptor kinase inhibitor attenuates sarcoma-induced nerve sprouting, neuroma formation and bone cancer pain. 6 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211349s000lbl.pdf biolink:NamedThing|biolink:Publication 2018 PMID:27908881 biolink:Article|biolink:NamedThing|biolink:Publication Lee LY, Hernandez D, Rajkhowa T, Smith SC, Raman JR, Nguyen B, Small D, Levis M 2017 2 Blood Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor 129 PMID:29724589 biolink:Article|biolink:NamedThing|biolink:Publication Miyazaki H, Ikeda Y, Sakurai O, Miyake T, Tsubota R, Okabe J, Kuroda M, Hisada Y, Yanagida T, Yoneda H, Tsukumo Y, Tokunaga S, Kawata T, Ohashi R, Fukuda H, Kojima K, Kannami A, Kifuji T, Sato N, Idei A, Iguchi T, Sakairi T, Moritani Y. 2018 11 Bioorg. Med. Chem. Lett. Discovery of evocalcet, a next-generation calcium-sensing receptor agonist for the treatment of hyperparathyroidism. 28 PMID:30267321 biolink:Article|biolink:NamedThing|biolink:Publication Syed YY 2018 15 Drugs Lanadelumab: First Global Approval. 78 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761090s000lbl.pdf biolink:NamedThing|biolink:Publication 2018 PMID:30411311 biolink:Article|biolink:NamedThing|biolink:Publication Keam SJ 2018 17 Drugs Vibegron: First Global Approval. 78 PMID:30465134 biolink:Article|biolink:NamedThing|biolink:Publication Duggan S 2018 18 Drugs Omidenepag Isopropyl Ophthalmic Solution 0.002%: First Global Approval. 78 PMID:30298461 biolink:Article|biolink:NamedThing|biolink:Publication Duggan S 2018 15 Drugs Caplacizumab: First Global Approval. 78 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761104s000lbl.pdf biolink:NamedThing|biolink:Publication 2018 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761089s000lbl.pdf biolink:NamedThing|biolink:Publication 2018 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761063s000lbl.pdf biolink:NamedThing|biolink:Publication 2018 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761097s000lbl.pdf biolink:NamedThing|biolink:Publication 2018 PMID:28265006 biolink:Article|biolink:NamedThing|biolink:Publication Burova E, Hermann A, Waite J, Potocky T, Lai V, Hong S, Liu M, Allbritton O, Woodruff A, Wu Q et al 2017 5 Mol. Cancer Ther. Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice. 16 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761107s000lbl.pdf biolink:NamedThing|biolink:Publication 2018 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761108s000lbl.pdf biolink:NamedThing|biolink:Publication 2018 PMID:29649283 biolink:Article|biolink:NamedThing|biolink:Publication Sheridan D, Yu ZX, Zhang Y, Patel R, Sun F, Lasaro MA, Bouchard K, Andrien B, Marozsan A, Wang Y et al 2018 4 PLoS ONE Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action 13 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761116s000lbl.pdf biolink:NamedThing|biolink:Publication 2018 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210854s000lbl.pdf biolink:NamedThing|biolink:Publication 2018 PMID:25531770 biolink:Article|biolink:NamedThing|biolink:Publication Stavros F, Yang A, Leon A, Nuttall M, Rasmussen HS 2014 12 PLoS ONE Characterization of structure and function of ZS-9, a K+ selective ion trap 9 PMID:25651699 biolink:Article|biolink:NamedThing|biolink:Publication Verma M, Pathak M, Shahab M, Singh K, Mitra K, Misra-Bhattacharya S 2014 6 Folia Parasitol (Praha) Moxidectin causes adult worm mortality of human lymphatic filarial parasite Brugia malayi in rodent models 61 PMID:23108553 biolink:Article|biolink:NamedThing|biolink:Publication Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimaraes FS 2012 1607 Philos Trans R Soc Lond B Biol Sci Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders 367 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210303Orig1s000lbl.pdf biolink:NamedThing|biolink:Publication 2018 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210795s000lbl.pdf biolink:NamedThing|biolink:Publication 2018 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210922s000lbl.pdf biolink:NamedThing|biolink:Publication 2018 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211172lbl.pdf biolink:NamedThing|biolink:Publication 2018 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf biolink:NamedThing|biolink:Publication 2019 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211371Orig1s000MultidisciplineR.pdf biolink:NamedThing|biolink:Publication 2019 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf biolink:NamedThing|biolink:Publication 2019 PMID:31144287 biolink:Article|biolink:NamedThing|biolink:Publication Al-Salama ZT 2019 9 Drugs Siponimod: First global approval 79 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf biolink:NamedThing|biolink:Publication 2019 PMID:31161538 biolink:Article|biolink:NamedThing|biolink:Publication Markham A 2019 9 Drugs Erdafitinib: First global approval 79 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212526s000lbl.pdf biolink:NamedThing|biolink:Publication 2019 PMID:31256368 biolink:Article|biolink:NamedThing|biolink:Publication Markham A 2019 11 Drugs Alpelisib: First global approval 79 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf biolink:NamedThing|biolink:Publication 2019 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212306s000lbl.pdf biolink:NamedThing|biolink:Publication 2019 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761121s000lbl.pdf biolink:NamedThing|biolink:Publication 2019 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf biolink:NamedThing|biolink:Publication 2019 PMID:26137992 biolink:Article|biolink:NamedThing|biolink:Publication Moilanen AM, Riikonen R, Oksala R, Ravanti L, Aho E, Wohlfahrt G, Nykanen PS, Tormakangas OP, Palvimo JJ, Kallio PJ 2015 Sci Rep Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies 5 https://www.ema.europa.eu/en/documents/assessment-report/waylivra-epar-public-assessment-report_en.pdf biolink:NamedThing|biolink:Publication 2019 PMID:31301033 biolink:Article|biolink:NamedThing|biolink:Publication Paik J, Duggan S 2019 12 Drugs Volanesorsen: First global approval 79 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761105s000lbl.pdf biolink:NamedThing|biolink:Publication 2019 PMID:25905918 biolink:Article|biolink:NamedThing|biolink:Publication Singh S, Kroe-Barrett RR, Canada KA, Zhu X, Sepulveda E, Wu H, He Y, Raymond EL, Ahlberg J, Frego LE, Amodeo LM, Catron KM, Presky DH, Hanke JH 2015 4 mAbs Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody 7 https://www.ema.europa.eu/en/documents/product-information/besremi-epar-product-information_en.pdf biolink:NamedThing|biolink:Publication 2019 https://www.ema.europa.eu/en/documents/product-information/zynquista-epar-product-information_en.pdf biolink:NamedThing|biolink:Publication 2019 PMID:22739142 biolink:Article|biolink:NamedThing|biolink:Publication Zambrowicz B, Freiman J, Brown PM, Frazier KS, Turnage A, Bronner J, Ruff D, Shadoan M, Banks P, Mseeh F, Rawlins DB, Goodwin NC, Mabon R, Harrison BA, Wilson A, Sands A, Powell DR 2012 2 Clin Pharmacol Ther LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial 92 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761079s000lbl.pdf biolink:NamedThing|biolink:Publication 2019 PMID:19754199 biolink:Article|biolink:NamedThing|biolink:Publication Chao Q, Sprankle KG, Grotzfeld RM, Lai AG, Carter TA, Velasco AM, Gunawardane RN, Cramer MD, Gardner MF, James J, Zarrinkar PP, Patel HK, Bhagwat SS 2009 23 J Med Chem Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor 52 PMID:19654408 biolink:Article|biolink:NamedThing|biolink:Publication Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B, Karaman MW, Pratz KW, Pallares G, Chao Q, Sprankle KG, Patel HK, Levis M, Armstrong RC, James J, Bhagwat SS 2009 14 Blood AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML) 114 https://clinicaltrials.gov/ProvidedDocs/61/NCT02215161/Prot_SAP_000.pdf biolink:NamedThing|biolink:Publication 2018 Phase II single agent study of selinexor (KPT-330) in patients with metastatic castration-resistant prostate cancer (MCRPC) and prior therapy with abiraterone and/or enzalutamide PMID:23183107 biolink:Article|biolink:NamedThing|biolink:Publication Moaddel R, Abdrakhmanova G, Kozak J, Jozwiak K, Toll L, Jimenez L, Rosenberg A, Tran T, Xiao Y, Zarate CA, Wainer IW 2013 1-3 Eur J Pharmacol Sub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in α7 nicotinic acetylcholine receptors 698 https://www.fda.gov/media/113279/download biolink:NamedThing|biolink:Publication 2018 PMID:12851303 biolink:Article|biolink:NamedThing|biolink:Publication Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY 2003 1 Ann N Y Acad Sci PT-141: a melanocortin agonist for the treatment of sexual dysfunction 994 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761085s000lbl.pdf biolink:NamedThing|biolink:Publication 2019 PMID:31383664 biolink:Article|biolink:NamedThing|biolink:Publication Tooke CL, Hinchliffe P, Lang PA, Mulholland AJ, Brem J, Schofield CJ, Spencer J 2019 10 Antimicrob Agents Chemother Molecular Basis of Class A beta-Lactamase Inhibition by Relebactam 23 PMID:26222558 biolink:Article|biolink:NamedThing|biolink:Publication Tap WD, Wainberg ZA, Anthony SP, Ibrahim PN, Zhang C, Healey JH, Chmielowski B, Staddon AP, Cohn AL, Shapiro GI, Keedy VL, Singh AS, Puzanov I, Kwak EL, Wagner AJ, Von Hoff DD, Weiss GJ, Ramanathan RK, Zhang J, Habets G, Zhang Y, Burton EA, Visor G, Sanftner L, Severson P, Nguyen H, Kim MJ, Marimuthu A, Tsang G, Shellooe R, Gee C, West BL, Hirth P, Nolop K, van de Rijn M, Hsu HH, Peterfy C, Lin PS, Tong-Starksen S, Bollag G 2015 5 N Engl J Med Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor 373 PMID:24170767 biolink:Article|biolink:NamedThing|biolink:Publication Liu N, Rowley BR, Bull CO, Schneider C, Haegebarth A, Schatz CA, Fracasso PR, Wilkie DP, Hentemann M, Wilhelm SM, Scott WJ, Mumberg D, Ziegelbauer K 2013 11 Mol. Cancer Ther. BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models. 12 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209936s000lbl.pdf biolink:NamedThing|biolink:Publication 2017 PMID:21293470 biolink:Article|biolink:NamedThing|biolink:Publication Ji XC, Zhao WH, Cao DX, Shi QQ, Wang XL 2011 2 Acta Pharmacol. Sin. Novel neuroprotectant chiral 3-n-butylphthalide inhibits tandem-pore-domain potassium channel TREK-1. 32 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208772lbl.pdf biolink:NamedThing|biolink:Publication 2017 PMID:28949138 biolink:Article|biolink:NamedThing|biolink:Publication Lynagh T, Romero-Rojo JL, Lund C, Pless SA 2017 J. Med. Chem. Molecular Basis for Allosteric Inhibition of Acid-Sensing Ion Channel 1a by Ibuprofen. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208716Orig1s000lbl.pdf biolink:NamedThing|biolink:Publication 2017 PMID:24919854 biolink:Article|biolink:NamedThing|biolink:Publication Gelbert LM, Cai S, Lin X, Sanchez-Martinez C, Del Prado M, Lallena MJ, Torres R, Ajamie RT, Wishart GN, Flack RS, Neubauer BL, Young J, Chan EM, Iversen P, Cronier D, Kreklau E, de Dios A 2014 5 Invest New Drugs Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. 32 PMID:21396362 biolink:Article|biolink:NamedThing|biolink:Publication Krauss AH, Impagnatiello F, Toris CB, Gale DC, Prasanna G, Borghi V, Chiroli V, Chong WK, Carreiro ST, Ongini E 2011 3 Exp. Eye Res. Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2α agonist, in preclinical models. 93 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209939Orig1s000,209940Orig1s000lbl.pdf biolink:NamedThing|biolink:Publication 2017 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761070s000lbl.pdf biolink:NamedThing|biolink:Publication 2017 PMID:26308095 biolink:Article|biolink:NamedThing|biolink:Publication Lau J, Bloch P, Schäffer L, Pettersson I, Spetzler J, Kofoed J, Madsen K, Knudsen LB, McGuire J, Steensgaard DB, Strauss HM, Gram DX, Knudsen SM, Nielsen FS, Thygesen P, Reedtz-Runge S, Kruse T 2015 18 J. Med. Chem. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. 58 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf biolink:NamedThing|biolink:Publication 2017 PMID:27072905 biolink:Article|biolink:NamedThing|biolink:Publication Sturdivant JM, Royalty SM, Lin CW, Moore LA, Yingling JD, Laethem CL, Sherman B, Heintzelman GR, Kopczynski CC, deLong MA 2016 10 Bioorg. Med. Chem. Lett. Discovery of the ROCK inhibitor netarsudil for the treatment of open-angle glaucoma. 26 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208254lbl.pdf biolink:NamedThing|biolink:Publication 2017 PMID:26641137 biolink:Article|biolink:NamedThing|biolink:Publication Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, Chaves J, Wierda WG, Awan FT, Brown JR, Hillmen P, Stephens DM, Ghia P, Barrientos JC, Pagel JM, Woyach J, Johnson D, Huang J, Wang X, Kaptein A, Lannutti BJ, Covey T, Fardis M, McGreivy J, Hamdy A, Rothbaum W, Izumi R, Diacovo TG, Johnson AJ, Furman RR 2016 4 N. Engl. J. Med. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. 374 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/210259s000lbl.pdf biolink:NamedThing|biolink:Publication 2017 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004131/WC500239033.pdf biolink:NamedThing|biolink:Publication 2017 PMID:16982756 biolink:Article|biolink:NamedThing|biolink:Publication Nakamura K, Taguchi E, Miura T, Yamamoto A, Takahashi K, Bichat F, Guilbaud N, Hasegawa K, Kubo K, Fujiwara Y, Suzuki R, Kubo K, Shibuya M, Isae T 2006 18 Cancer Res. KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. 66 PMID:14623894 biolink:Article|biolink:NamedThing|biolink:Publication Pham V, Wade JD, Purdue BW, Sexton PM 2004 8 J. Biol. Chem. Spatial proximity between a photolabile residue in position 19 of salmon calcitonin and the amino terminus of the human calcitonin receptor. 279 PMID:10385705 biolink:Article|biolink:NamedThing|biolink:Publication Christopoulos G, Perry KJ, Morfis M, Tilakaratne N, Gao Y, Fraser NJ, Main MJ, Foord SM, Sexton PM 1999 1 Mol. Pharmacol. Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. 56 PMID:15692146 biolink:Article|biolink:NamedThing|biolink:Publication Hay DL, Christopoulos G, Christopoulos A, Poyner DR, Sexton PM 2005 5 Mol. Pharmacol. Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes. 67 PMID:21449606 biolink:Article|biolink:NamedThing|biolink:Publication Mascitti V, Maurer TS, Robinson RP, Bian J, Boustany-Kari CM, Brandt T, Collman BM, Kalgutkar AS, Klenotic MK, Leininger MT, Lowe A, Maguire RJ, Masterson VM, Miao Z, Mukaiyama E, Patel JD, Pettersen JC, Préville C, Samas B, She L, Sobol Z, Steppan CM, Stevens BD, Thuma BA, Tugnait M, Zeng D, Zhu T 2011 8 J. Med. Chem. Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors. 54 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209803s000lbl.pdf biolink:NamedThing|biolink:Publication 2017 PMID:10193788 biolink:Article|biolink:NamedThing|biolink:Publication Vanderheyden PM, Fierens FL, De Backer JP, Fraeyman N, Vauquelin G 1999 4 Br. J. Pharmacol. Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1 receptors. 126 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209360s000lbl.pdf biolink:NamedThing|biolink:Publication 2017 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209360s000lbl.pdf biolink:NamedThing|biolink:Publication 2018 PMID:22266222 biolink:Article|biolink:NamedThing|biolink:Publication Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, Chen Y, Grillot K, Bischoff ED, Cai L, Aparicio A, Dorow S, Arora V, Shao G, Qian J, Zhao H, Yang G, Cao C, Sensintaffar J, Wasielewska T, Herbert MR, Bonnefous C, Darimont B, Scher HI, Smith-Jones P, Klang M, Smith ND, De Stanchina E, Wu N, Ouerfelli O, Rix PJ, Heyman RA, Jung ME, Sawyers CL, Hager JH 2012 6 Cancer Res. ARN-509: a novel antiandrogen for prostate cancer treatment. 72 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210951s000lbl.pdf biolink:NamedThing|biolink:Publication 2018 PMID:22711801 biolink:Article|biolink:NamedThing|biolink:Publication Gregori-Puigjané E, Setola V, Hert J, Crews BA, Irwin JJ, Lounkine E, Marnett L, Roth BL, Shoichet BK 2012 28 Proc. Natl. Acad. Sci. U.S.A. Identifying mechanism-of-action targets for drugs and probes. 109 PMID:9628722 biolink:Article|biolink:NamedThing|biolink:Publication Miles RW, Tyler PC, Furneaux RH, Bagdassarian CK, Schramm VL 1998 24 Biochemistry One-third-the-sites transition-state inhibitors for purine nucleoside phosphorylase. 37 PMID:17897085 biolink:Article|biolink:NamedThing|biolink:Publication Korycka A, Błoński JZ, Robak T 2007 9 Mini Rev Med Chem Forodesine (BCX-1777, Immucillin H)--a new purine nucleoside analogue: mechanism of action and potential clinical application. 7 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997Orig1Orig2s000lbl.pdf biolink:NamedThing|biolink:Publication 2017 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208743lbl.pdf biolink:NamedThing|biolink:Publication 2017 PMID:26562265 biolink:Article|biolink:NamedThing|biolink:Publication Hattersley G, Dean T, Corbin BA, Bahar H, Gardella TJ 2016 1 Endocrinology Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling. 157 PMID:27780853 biolink:Article|biolink:NamedThing|biolink:Publication Zhang S, Anjum R, Squillace R, Nadworny S, Zhou T, Keats J, Ning Y, Wardwell SD, Miller D, Song Y, Eichinger L, Moran L, Huang WS, Liu S, Zou D, Wang Y, Mohemmad Q, Jang HG, Ye E, Narasimhan N, Wang F, Miret J, Zhu X, Clackson T, Dalgarno D, Shakespeare WC, Rivera VM 2016 22 Clin. Cancer Res. The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models. 22 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761069s000lbl.pdf biolink:NamedThing|biolink:Publication 2017 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761052lbl.pdf biolink:NamedThing|biolink:Publication 2017 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b7aa0bae-255b-4792-a963-6606370a175f biolink:NamedThing|biolink:Publication 2009 https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050740s021lbl.pdf biolink:NamedThing|biolink:Publication 2012 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761037s000lbl.pdf biolink:NamedThing|biolink:Publication 2017 PMID:14761182 biolink:Article|biolink:NamedThing|biolink:Publication Shin SS, Byun Y, Lim KM, Choi JK, Lee KW, Moh JH, Kim JK, Jeong YS, Kim JY, Choi YH, Koh HJ, Park YH, Oh YI, Noh MS, Chung S 2004 4 J. Med. Chem. In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives. 47 PMID:21570283 biolink:Article|biolink:NamedThing|biolink:Publication Kim HJ, Kwak WY, Min JP, Lee JY, Yoon TH, Kim HD, Shin CY, Kim MK, Choi SH, Kim HS, Yang EK, Cheong YH, Chae YN, Park KJ, Jang JM, Choi SJ, Son MH, Kim SH, Yoo M, Lee BJ 2011 12 Bioorg. Med. Chem. Lett. Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. 21 PMID:21093089 biolink:Article|biolink:NamedThing|biolink:Publication Cho JM, Jang HW, Cheon H, Jeong YT, Kim DH, Lim YM, Choi SH, Yang EK, Shin CY, Son MH, Kim SH, Kim HJ, Lee MS 2011 1 Diabetes Res. Clin. Pract. A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing β-cell replication and neogenesis. 91 PMID:22278334 biolink:Article|biolink:NamedThing|biolink:Publication Skarke C, Alamuddin N, Lawson JA, Cen L, Propert KJ, Fitzgerald GA 2012 6 Clin. Pharmacol. Ther. Comparative impact on prostanoid biosynthesis of celecoxib and the novel nonsteroidal anti-inflammatory drug CG100649. 91 PMID:19297154 biolink:Article|biolink:NamedThing|biolink:Publication Zhang P, Huang W, Wang L, Bao L, Jia ZJ, Bauer SM, Goldman EA, Probst GD, Song Y, Su T, Fan J, Wu Y, Li W, Woolfrey J, Sinha U, Wong PW, Edwards ST, Arfsten AE, Clizbe LA, Kanter J, Pandey A, Park G, Hutchaleelaha A, Lambing JL, Hollenbach SJ, Scarborough RM, Zhu BY 2009 8 Bioorg. Med. Chem. Lett. Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor. 19 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208383s000lbl.pdf biolink:NamedThing|biolink:Publication 2017 PMID:1446593 biolink:Article|biolink:NamedThing|biolink:Publication LaPolt PS, Nishimori K, Fares FA, Perlas E, Boime I, Hsueh AJ 1992 6 Endocrinology Enhanced stimulation of follicle maturation and ovulatory potential by long acting follicle-stimulating hormone agonists with extended carboxyl-terminal peptides. 131 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761061s000lbl.pdf biolink:NamedThing|biolink:Publication 2017 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004119/WC500231261.pdf biolink:NamedThing|biolink:Publication 2017 PMID:17553678 biolink:Article|biolink:NamedThing|biolink:Publication Yamazaki Y, Abe K, Toma T, Nishikawa M, Ozawa H, Okuda A, Araki T, Oda S, Inoue K, Shibuya K, Staels B, Fruchart JC 2007 16 Bioorg. Med. Chem. Lett. Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor alpha agonists. 17 DOI: biolink:Article|biolink:NamedThing|biolink:Publication Bai AP, Guo ZR, Hu WH, Shen F, Cheng GF. 2001 9 Chin Chem Lett Design, synthesis and in vitro evaluation of a new class of novel cyclooxygenase-2 inhibitors: 3,4-diaryl-3-pyrrolin-2-ones. 12 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209195s000lbl.pdf biolink:NamedThing|biolink:Publication 2017 PMID:28193778 biolink:Article|biolink:NamedThing|biolink:Publication Yen K, Travins J, Wang F, David MD, Artin E, Straley K, Padyana A, Gross S, DeLaBarre B, Tobin E, Chen Y, Nagaraja R, Choe S, Jin L, Konteatis Z, Cianchetta G, Saunders JO, Salituro FG, Quivoron C, Opolon P, Bawa O, Saada V, Paci A, Broutin S, Bernard OA, de Botton S, Marteyn BS, Pilichowska M, Xu Y, Fang C, Jiang F, Wei W, Jin S, Silverman L, Liu W, Yang H, Dang L, Dorsch M, Penard-Lacronique V, Biller SA, Su SM 2017 5 Cancer Discov AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations. 7 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209606s000lbl.pdf biolink:NamedThing|biolink:Publication 2017 PMID:15715478 biolink:Article|biolink:NamedThing|biolink:Publication Tsou HR, Overbeek-Klumpers EG, Hallett WA, Reich MF, Floyd MB, Johnson BD, Michalak RS, Nilakantan R, Discafani C, Golas J, Rabindran SK, Shen R, Shi X, Wang YF, Upeslacis J, Wissner A 2005 4 J. Med. Chem. Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity. 48 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208051s000lbl.pdf biolink:NamedThing|biolink:Publication 2017 PMID:15210067 biolink:Article|biolink:NamedThing|biolink:Publication Chen XH, Bai JY, Shen F, Bai AP, Guo ZR, Cheng GF 2004 7 Acta Pharmacol. Sin. Imrecoxib: a novel and selective cyclooxygenase 2 inhibitor with anti-inflammatory effect. 25 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004209/WC500232105.pdf biolink:NamedThing|biolink:Publication 2017 http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209115s000lbl.pdf biolink:NamedThing|biolink:Publication 2016 DOI:10.1021/acs.jmedchem.6b00990 biolink:Article|biolink:NamedThing|biolink:Publication Thorsell, Ann-Gerd and Ekblad, Torun and Karlberg, Tobias and Löw, Mirjam and Pinto, Ana Filipa and Tresaugues, Lionel and Moche, Martin and Cohen, Michael S. and Schüler, Herwig 2016 J. Med. Chem. Structural basis for potency and promiscuity in poly(ADP-ribose) polymerase (PARP) and tankyrase inhibitors PMID:20188549 biolink:Article|biolink:NamedThing|biolink:Publication Zhang YK, Plattner JJ, Akama T, Baker SJ, Hernandez VS, Sanders V, Freund Y, Kimura R, Bu W, Hold KM, Lu XS 2010 7 Bioorg. Med. Chem. Lett. Design and synthesis of boron-containing PDE4 inhibitors using soft-drug strategy for potential dermatologic anti-inflammatory application. 20 http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207695s000lbl.pdf biolink:NamedThing|biolink:Publication 2016 http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125293s085lbl.pdf biolink:NamedThing|biolink:Publication 2016 PMID:20363976 biolink:Article|biolink:NamedThing|biolink:Publication Fridman JS, Scherle PA, Collins R, Burn TC, Li Y, Li J, Covington MB, Thomas B, Collier P, Favata MF, Wen X, Shi J, McGee R, Haley PJ, Shepard S, Rodgers JD, Yeleswaram S, Hollis G, Newton RC, Metcalf B, Friedman SM, Vaddi K 2010 9 J. Immunol. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. 184 PMID:22959248 biolink:Article|biolink:NamedThing|biolink:Publication Hu S, Xie G, Zhang DX, Davis C, Long W, Hu Y, Wang F, Kang X, Tan F, Ding L, Wang Y 2012 19 Bioorg. Med. Chem. Lett. Synthesis and biological evaluation of crown ether fused quinazoline analogues as potent EGFR inhibitors. 22 PMID:22088449 biolink:Article|biolink:NamedThing|biolink:Publication Wang HP, Zhang L, Wang YX, Tan FL, Xia Y, Ren GJ, Hu P, Jiang J, Wang MZ, Xiao Y 2011 13 Chin. Med. J. Phase I trial of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in Chinese patients with non-small cell lung cancer. 124 PMID:27357069 biolink:Article|biolink:NamedThing|biolink:Publication Kim ES 2016 11 Drugs Olmutinib: First Global Approval. 76 http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208745lbl.pdf biolink:NamedThing|biolink:Publication 2017 PMID:26558155 biolink:Article|biolink:NamedThing|biolink:Publication Shailubhai K, Palejwala V, Arjunan KP, Saykhedkar S, Nefsky B, Foss JA, Comiskey S, Jacob GS, Plevy SE 2015 4 World J Gastrointest Pharmacol Ther Plecanatide and dolcanatide, novel guanylate cyclase-C agonists, ameliorate gastrointestinal inflammation in experimental models of murine colitis. 6 PMID:24900196 biolink:Article|biolink:NamedThing|biolink:Publication Xu L, Liu H, Murray BP, Callebaut C, Lee MS, Hong A, Strickley RG, Tsai LK, Stray KM, Wang Y, Rhodes GR, Desai MC 2010 5 ACS Med Chem Lett Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer. 1 http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203094s005lbl.pdf biolink:NamedThing|biolink:Publication 2016 PMID:25676420 biolink:Article|biolink:NamedThing|biolink:Publication Zabriskie MS, Vellore NA, Gantz KC, Deininger MW, O'Hare T 2015 9 Leukemia Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1. 29 PMID:21443688 biolink:Article|biolink:NamedThing|biolink:Publication Tian S, Quan H, Xie C, Guo H, Lü F, Xu Y, Li J, Lou L 2011 7 Cancer Sci. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. 102 PMID:28041831 biolink:Article|biolink:NamedThing|biolink:Publication Goldberg DR, De Lombaert S, Aiello R, Bourassa P, Barucci N, Zhang Q, Paralkar V, Stein AJ, Holt M, Valentine J, Zavadoski W 2017 3 Bioorg. Med. Chem. Lett. Optimization of spirocyclic proline tryptophan hydroxylase-1 inhibitors. 27 http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125359s088lbl.pdf biolink:NamedThing|biolink:Publication 2016 http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208794s000lbl.pdf biolink:NamedThing|biolink:Publication 2017 PMID:11314603 biolink:Article|biolink:NamedThing|biolink:Publication Nagatomo T, Hosohata Y, Ohnuki T, Nakamura T, Hattori K, Suzuki J, Ishiguro M 2001 1 Cardiovasc Drug Rev Bopindolol: pharmacological basis and clinical implications. 19 PMID:12152654 biolink:Article|biolink:NamedThing|biolink:Publication Gils A, Stassen JM, Nar H, Kley JT, Wienen W, Ries UJ, Declerck PJ 2002 1 Thromb. Haemost. Characterization and comparative evaluation of a novel PAI-1 inhibitor. 88 http://www.medicines.org.uk/emc/medicine/1073 biolink:NamedThing|biolink:Publication 2017 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004085/WC500223723.pdf biolink:NamedThing|biolink:Publication 2017 PMID:27144355 biolink:Article|biolink:NamedThing|biolink:Publication Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, Alkondon M, Yuan P, Pribut HJ, Singh NS, Dossou KS, Fang Y, Huang XP, Mayo CL, Wainer IW, Albuquerque EX, Thompson SM, Thomas CJ, Zarate CA, Gould TD 2016 7604 Nature NMDAR inhibition-independent antidepressant actions of ketamine metabolites. 533 http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209092s000lbl.pdf biolink:NamedThing|biolink:Publication 2017 PMID:25941111 biolink:Article|biolink:NamedThing|biolink:Publication VanArsdale T, Boshoff C, Arndt KT, Abraham RT 2015 13 Clin. Cancer Res. Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment. 21 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208854s000lbl.pdf biolink:NamedThing|biolink:Publication 2017 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208447lbl.pdf biolink:NamedThing|biolink:Publication 2017 http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761049s000lbl.pdf biolink:NamedThing|biolink:Publication 2017 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761053lbl.pdf biolink:NamedThing|biolink:Publication 2017 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761055lbl.pdf biolink:NamedThing|biolink:Publication 2017 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208082s000lbl.pdf biolink:NamedThing|biolink:Publication 2017 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209241lbl.pdf biolink:NamedThing|biolink:Publication 2017 PMID:22455412 biolink:Article|biolink:NamedThing|biolink:Publication Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, Kricorian G, Aras G, Li J, Russell CB, Thompson EH, Baumgartner S 2012 13 N. Engl. J. Med. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. 366 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003995/WC500217100.pdf biolink:NamedThing|biolink:Publication 2016 http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761046s000lbl.pdf biolink:NamedThing|biolink:Publication 2016 PMID:9537821 biolink:Article|biolink:NamedThing|biolink:Publication Tatsumi M, Groshan K, Blakely RD, Richelson E 1997 2-3 Eur. J. Pharmacol. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. 340 http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761038lbl.pdf biolink:NamedThing|biolink:Publication 2016 PMID:24900456 biolink:Article|biolink:NamedThing|biolink:Publication Zhong M, Gadek TR, Bui M, Shen W, Burnier J, Barr KJ, Hanan EJ, Oslob JD, Yu CH, Zhu J, Arkin MR, Evanchik MJ, Flanagan WM, Hoch U, Hyde J, Prabhu S, Silverman JA, Wright J 2012 3 ACS Med Chem Lett Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye. 3 http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208073s000lbl.pdf biolink:NamedThing|biolink:Publication 2016 http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208524s000lbl.pdf biolink:NamedThing|biolink:Publication 2016 PMID:23301156 biolink:Article|biolink:NamedThing|biolink:Publication Realini N, Solorzano C, Pagliuca C, Pizzirani D, Armirotti A, Luciani R, Costi MP, Bandiera T, Piomelli D 2013 Sci Rep Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity. 3 PMID:24113750 biolink:Article|biolink:NamedThing|biolink:Publication MacKenzie AE, Caltabiano G, Kent TC, Jenkins L, McCallum JE, Hudson BD, Nicklin SA, Fawcett L, Markwick R, Charlton SJ, Milligan G 2014 1 Mol. Pharmacol. The antiallergic mast cell stabilizers lodoxamide and bufrolin as the first high and equipotent agonists of human and rat GPR35. 85 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000253/WC500040495.pdf biolink:NamedThing|biolink:Publication 2016 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125499s009lbl.pdf biolink:NamedThing|biolink:Publication 2015 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103628s5258lbl.pdf biolink:NamedThing|biolink:Publication 2015 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103471s5188lbl.pdf biolink:NamedThing|biolink:Publication 2015 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103172s5203lbl.pdf biolink:NamedThing|biolink:Publication 2015 PMID:16469866 biolink:Article|biolink:NamedThing|biolink:Publication Vanover KE, Weiner DM, Makhay M, Veinbergs I, Gardell LR, Lameh J, Del Tredici AL, Piu F, Schiffer HH, Ott TR, Burstein ES, Uldam AK, Thygesen MB, Schlienger N, Andersson CM, Son TY, Harvey SC, Powell SB, Geyer MA, Tolf BR, Brann MR, Davis RE 2006 2 J. Pharmacol. Exp. Ther. Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist. 317 http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207318lbl.pdf biolink:NamedThing|biolink:Publication 2016 PMID:24847974 biolink:Article|biolink:NamedThing|biolink:Publication Lanier M, Ambrus G, Cole DC, Davenport R, Ellery J, Fosbeary R, Jennings AJ, Kadotani A, Kamada Y, Kamran R, Matsumoto S, Mizukami A, Okubo S, Okada K, Saikatendu K, Walsh L, Wu H, Hixon MS 2014 12 J. Med. Chem. A fragment-based approach to identifying S-adenosyl-l-methionine -competitive inhibitors of catechol O-methyl transferase (COMT). 57 http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761034s000lbl.pdf biolink:NamedThing|biolink:Publication 2016 PMID:9713295 biolink:Article|biolink:NamedThing|biolink:Publication Denis L, Debruyne F, De Porre P, Bruynseels J 1998 4 Eur. J. Cancer Early clinical experience with liarozole (Liazal) in patients with progressive prostate cancer. 34 PMID:21762037 biolink:Article|biolink:NamedThing|biolink:Publication Antoniu SA 2011 11 Expert Opin. Ther. Targets Terguride for pulmonary arterial hypertension. 15 PMID:15627429 biolink:Article|biolink:NamedThing|biolink:Publication Thierry C, Boeynaems JM, Paolo M 2005 3 Eur. J. Pharmacol. Actions of tilidine and nortilidine on cloned opioid receptors. 506 PMID:11523024 biolink:Article|biolink:NamedThing|biolink:Publication Karp JE 2001 3 Suppl 7 Semin. Hematol. Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies. 38 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004059/WC500208434.pdf biolink:NamedThing|biolink:Publication 2016 PMID:12166927 biolink:Article|biolink:NamedThing|biolink:Publication Pellicciari R, Fiorucci S, Camaioni E, Clerici C, Costantino G, Maloney PR, Morelli A, Parks DJ, Willson TM 2002 17 J. Med. Chem. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. 45 http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207999s000lbl.pdf biolink:NamedThing|biolink:Publication 2016 PMID:8736619 biolink:Article|biolink:NamedThing|biolink:Publication Patel SS, Wilde MI 1996 6 Drugs Ebrotidine. 51 PMID:7693433 biolink:Article|biolink:NamedThing|biolink:Publication Goa KL, Brogden RN 1993 3 Drugs Propiram. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use as an analgesic. 46 PMID:6141283 biolink:Article|biolink:NamedThing|biolink:Publication Spiegel K, Pasternak GW 1984 2 J. Pharmacol. Exp. Ther. Meptazinol: a novel Mu-1 selective opioid analgesic. 228 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103951s5363lbl.pdf biolink:NamedThing|biolink:Publication 2015 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103964s5264lbl.pdf biolink:NamedThing|biolink:Publication 2015 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000116/WC500024979.pdf biolink:NamedThing|biolink:Publication 2015 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103949s5299lbl.pdf biolink:NamedThing|biolink:Publication 2015 http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125164s071s072s073lbl.pdf biolink:NamedThing|biolink:Publication 2016 PMID:10776839 biolink:Article|biolink:NamedThing|biolink:Publication Dunn CJ, Goa KL 2000 3 Drugs Lenograstim: an update of its pharmacological properties and use in chemotherapy-induced neutropenia and related clinical settings. 59 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000872/WC500054377.pdf biolink:NamedThing|biolink:Publication 2015 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022081s033lbl.pdf biolink:NamedThing|biolink:Publication 2015 PMID:9875499 biolink:Article|biolink:NamedThing|biolink:Publication Lee JH, Lee JM, Kim JK, Ahn SK, Lee SJ, Kim MY, Jew SS, Park JG, Hong CI 1998 5 Arch. Pharm. Res. Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor. 21 http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208341s000lbl.pdf biolink:NamedThing|biolink:Publication 2016 PMID:2853885 biolink:Article|biolink:NamedThing|biolink:Publication Scherman D, Hamon M, Gozlan H, Henry JP, Lesage A, Masson M, Rumigny JF 1988 6 Prog. Neuropsychopharmacol. Biol. Psychiatry Molecular pharmacology of niaprazine. 12 PMID:23291630 biolink:Article|biolink:NamedThing|biolink:Publication Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, Huang DC, Hymowitz SG, Jin S, Khaw SL, Kovar PJ, Lam LT, Lee J, Maecker HL, Marsh KC, Mason KD, Mitten MJ, Nimmer PM, Oleksijew A, Park CH, Park CM, Phillips DC, Roberts AW, Sampath D, Seymour JF, Smith ML, Sullivan GM, Tahir SK, Tse C, Wendt MD, Xiao Y, Xue JC, Zhang H, Humerickhouse RA, Rosenberg SH, Elmore SW 2013 2 Nat. Med. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. 19 http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208573s000lbl.pdf biolink:NamedThing|biolink:Publication 2016 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103532s5175lbl.pdf biolink:NamedThing|biolink:Publication 2014 PMID:20040696 biolink:Article|biolink:NamedThing|biolink:Publication Gish EC, Miller JL, Honey BL, Johnson PN 2010 2 Ann Pharmacother Lofexidine, an {alpha}2-receptor agonist for opioid detoxification. 44 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103411s5180lbl.pdf biolink:NamedThing|biolink:Publication 2014 http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208261Orig1s000lbl.pdf biolink:NamedThing|biolink:Publication 2016 http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2011/05/WC500106736.pdf biolink:NamedThing|biolink:Publication 2013 PMID:12487507 biolink:Article|biolink:NamedThing|biolink:Publication Ishide T 2002 7 Curr Med Res Opin Denopamine, a selective beta1-receptor agonist and a new coronary vasodilator. 18 PMID:7726994 biolink:Article|biolink:NamedThing|biolink:Publication Wouters W, Snoeck E, De Coster R 1994 1 Breast Cancer Res. Treat. Vorozole, a specific non-steroidal aromatase inhibitor. 30 http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/21396_prempro_lbl.pdf biolink:NamedThing|biolink:Publication 2003 PMID:2154989 biolink:Article|biolink:NamedThing|biolink:Publication Morii M, Takata H, Fujisaki H, Takeguchi N 1990 4 Biochem. Pharmacol. The potency of substituted benzimidazoles such as E3810, omeprazole, Ro 18-5364 to inhibit gastric H+, K(+)-ATPase is correlatedwith the rate of acid-activation of the inhibitor. 39 PMID:11304936 biolink:Article|biolink:NamedThing|biolink:Publication Kwon D, Chae JB, Park CW, Kim YS, Lee SM, Kim EJ, Huh IH, Kim DY, Cho KD 2001 3 Arzneimittelforschung Effects of IY-81149, a newly developed proton pump inhibitor, on gastric acid secretion in vitro and in vivo. 51 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021825s003lbl.pdf biolink:NamedThing|biolink:Publication 2015 PMID:9298526 biolink:Article|biolink:NamedThing|biolink:Publication Uneyama H, Takahara A, Dohmoto H, Yoshimoto R, Inoue K, Akaike N 1997 1 Br. J. Pharmacol. Blockade of N-type Ca2+ current by cilnidipine (FRC-8653) in acutely dissociated rat sympathetic neurones. 122 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/019481s013lbl.pdf biolink:NamedThing|biolink:Publication 2015 PMID:4859983 biolink:Article|biolink:NamedThing|biolink:Publication Casdorph HR 1967 4 Calif Med Hypercholesteremia. Treatment with cholestyramine, a bile acid sequestering resin. 106 http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/016267s050lbl.pdf biolink:NamedThing|biolink:Publication 2011 PMID:2547493 biolink:Article|biolink:NamedThing|biolink:Publication Klöckner U, Isenberg G 1989 3 Br. J. Pharmacol. The dihydropyridine niguldipine modulates calcium and potassium currents in vascular smooth muscle cells. 97 PMID:8287905 biolink:Article|biolink:NamedThing|biolink:Publication Tohse N, Takeda Y, Kanno M 1993 2 Eur. J. Pharmacol. Voltage-dependent modulation of L-type Ca2+ current by manidipine in guinea-pig heart cells. 249 PMID:7898101 biolink:Article|biolink:NamedThing|biolink:Publication Rosenthal J 1994 J. Cardiovasc. Pharmacol. Nilvadipine: profile of a new calcium antagonist. An overview. 24 Suppl 2 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000802/WC500026565.pdf biolink:NamedThing|biolink:Publication 2016 PMID:22455413 biolink:Article|biolink:NamedThing|biolink:Publication Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, Braun D, Banerjee S 2012 13 N. Engl. J. Med. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. 366 PMID:10533013 biolink:Article|biolink:NamedThing|biolink:Publication Wright RO, Lewander WJ, Woolf AD 1999 5 Ann Emerg Med Methemoglobinemia: etiology, pharmacology, and clinical management. 34 PMID:12749884 biolink:Article|biolink:NamedThing|biolink:Publication Faul MM, Gillig JR, Jirousek MR, Ballas LM, Schotten T, Kahl A, Mohr M 2003 11 Bioorg. Med. Chem. Lett. Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCbeta. 13 PMID:16891464 biolink:Article|biolink:NamedThing|biolink:Publication Rizvi MA, Ghias K, Davies KM, Ma C, Weinberg F, Munshi HG, Krett NL, Rosen ST 2006 7 Mol. Cancer Ther. Enzastaurin (LY317615), a protein kinase Cbeta inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines. 5 PMID:9126675 biolink:Article|biolink:NamedThing|biolink:Publication Scholz H 1997 Cardiovasc Drugs Ther Pharmacological aspects of calcium channel blockers. 10 Suppl 3 PMID:17213004 biolink:Article|biolink:NamedThing|biolink:Publication Park JY, Kim KA, Park PW, Lee OJ, Ryu JH, Lee GH, Ha MC, Kim JS, Kang SW, Lee KR 2006 11 Clin Ther Pharmacokinetic and pharmacodynamic characteristics of a new S-amlodipine formulation in healthy Korean male subjects: a randomized, open-label, two-period, comparative, crossover study. 28 PMID:8821512 biolink:Article|biolink:NamedThing|biolink:Publication Guarneri L, Angelico P, Ibba M, Poggesi E, Taddei C, Leonardi A, Testa R 1996 1 Arzneimittelforschung Pharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine. 46 http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/077394lbl.pdf biolink:NamedThing|biolink:Publication 2005 http://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21160lbl.pdf biolink:NamedThing|biolink:Publication 2001 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022127s011lbl.pdf biolink:NamedThing|biolink:Publication 2014 http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019071s012lbl.pdf biolink:NamedThing|biolink:Publication 2009 PMID:18655903 biolink:Article|biolink:NamedThing|biolink:Publication Manning M, Stoev S, Chini B, Durroux T, Mouillac B, Guillon G 2008 Prog. Brain Res. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. 170 http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203756lbl.pdf biolink:NamedThing|biolink:Publication 2012 http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020452s005lbl.pdf biolink:NamedThing|biolink:Publication 2010 http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050682s029s030lbl.pdf biolink:NamedThing|biolink:Publication 2012 http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020221s024lbl.pdf biolink:NamedThing|biolink:Publication 2008 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020954s014lbl.pdf biolink:NamedThing|biolink:Publication 2015 http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020038s033lbl.pdf biolink:NamedThing|biolink:Publication 2010 PMID:3025043 biolink:Article|biolink:NamedThing|biolink:Publication Yoshida T, Nishioka H, Yoshioka K, Nakano K, Kondo M, Terashima H 1987 1 Diabetes Effect of aldose reductase inhibitor ONO 2235 on reduced sympathetic nervous system activity and peripheral nerve disorders in STZ-induced diabetic rats. 36 PMID:1278093 biolink:Article|biolink:NamedThing|biolink:Publication Taurog A 1976 4 Endocrinology The mechanism of action of the thioureylene antithyroid drugs. 98 PMID:6356910 biolink:Article|biolink:NamedThing|biolink:Publication Kerwar SS 1983 4B Am. J. Med. Pharmacologic properties of fenbufen. 75 PMID:23755755 biolink:Article|biolink:NamedThing|biolink:Publication Maenthaisong R, Tacconelli S, Sritara P, Del Boccio P, Di Francesco L, Sacchetta P, Archararit N, Aryurachai K, Patrignani P, Suthisisang C 2 Int J Immunopathol Pharmacol Clinical pharmacology of cyclooxygenase inhibition and pharmacodynamic interaction with aspirin by floctafenine in Thai healthy subjects. 26 http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103767s5119lbl.pdf biolink:NamedThing|biolink:Publication 2011 http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125036s0144lbl.pdf biolink:NamedThing|biolink:Publication 2012 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125118s179lbl.pdf biolink:NamedThing|biolink:Publication 2014 http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207155s000lbl.pdf biolink:NamedThing|biolink:Publication 2016 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125288s062lbl.pdf biolink:NamedThing|biolink:Publication 2014 http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125521s000lbl.pdf biolink:NamedThing|biolink:Publication 2016 http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125509lbl.pdf biolink:NamedThing|biolink:Publication 2016 http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761033lbl.pdf biolink:NamedThing|biolink:Publication 2016 http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/125249lbl.pdf biolink:NamedThing|biolink:Publication 2008 http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021846s101lbl.pdf biolink:NamedThing|biolink:Publication 2008 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205109s001lbl.pdf biolink:NamedThing|biolink:Publication 2014 http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020057s034lbl.pdf biolink:NamedThing|biolink:Publication 2006 http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/UCM200875.pdf biolink:NamedThing|biolink:Publication 2000 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208462lbl.pdf biolink:NamedThing|biolink:Publication 2015 PMID:20160034 biolink:Article|biolink:NamedThing|biolink:Publication Kupperman E, Lee EC, Cao Y, Bannerman B, Fitzgerald M, Berger A, Yu J, Yang Y, Hales P, Bruzzese F, Liu J, Blank J, Garcia K, Tsu C, Dick L, Fleming P, Yu L, Manfredi M, Rolfe M, Bolen J 2010 5 Cancer Res. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. 70 PMID:18500360 biolink:Article|biolink:NamedThing|biolink:Publication Matagne A, Margineanu DG, Kenda B, Michel P, Klitgaard H 2008 8 Br. J. Pharmacol. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. 154 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761036Orig1s000lbledt.pdf biolink:NamedThing|biolink:Publication 2015 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/101063s5169lbl.pdf biolink:NamedThing|biolink:Publication 2013 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125547s000lbl.pdf biolink:NamedThing|biolink:Publication 2015 PMID:2905151 biolink:Article|biolink:NamedThing|biolink:Publication Vincent J, Sumner DJ, Reid JL 1988 5 Br J Clin Pharmacol Ebastine: the effect of a new antihistamine on psychomotor performance and autonomic responses in healthy subjects. 26 PMID:1982751 biolink:Article|biolink:NamedThing|biolink:Publication Porszász J, Varga F, Porszász KG, Szolscányi J, Barthó L, Petöcz L, Kápolnai L 1990 12 Arzneimittelforschung Pharmacology of the new H1-receptor antagonist setastine hydrochloride. 40 PMID:1354949 biolink:Article|biolink:NamedThing|biolink:Publication Rosenzweig P, Thebault JJ, Caplain H, Dubruc C, Bianchetti G, Fuseau E, Morselli PL 1992 2 Ann Allergy Pharmacodynamics and pharmacokinetics of mizolastine (SL 85.0324), a new nonsedative H1 antihistamine. 69 PMID:13499132 biolink:Article|biolink:NamedThing|biolink:Publication LENKE D 1957 11 Arzneimittelforschung [Pharmacological effects of phathalazine and phthalazone derivatives. I]. 7 PMID:13757612 biolink:Article|biolink:NamedThing|biolink:Publication KOHOUT J, KORBOVA L, BLAZEK K 1961 Cas. Lek. Cesk. [Effect of anthistaminic drugs on the appearance of experimental gastric ulcer. III. Effect of mephenhydramine (alphadril) and polydroxyethylenesorbitanmonooleate on the appearance of gastric ulcers in guinea pigs]. 100 PMID:17404836 biolink:Article|biolink:NamedThing|biolink:Publication Ramadan ZB, Wrang ML, Tipton KF 2007 10 Neurochem. Res. Species differences in the selective inhibition of monoamine oxidase (1-methyl-2-phenylethyl)hydrazine and its potentiation by cyanide. 32 PMID:5889715 biolink:Article|biolink:NamedThing|biolink:Publication Gilmour SJ 1965 478 Br J Psychiatry Clinical trial of mebanazine--a new monoamine oxidase inhibitor. 111 PMID:19582593 biolink:Article|biolink:NamedThing|biolink:Publication Uebele VN, Nuss CE, Fox SV, Garson SL, Cristescu R, Doran SM, Kraus RL, Santarelli VP, Li Y, Barrow JC, Yang ZQ, Schlegel KA, Rittle KE, Reger TS, Bednar RA, Lemaire W, Mullen FA, Ballard JE, Tang C, Dai G, McManus OB, Koblan KS, Renger JJ 2009 2 Cell Biochem. Biophys. Positive allosteric interaction of structurally diverse T-type calcium channel antagonists. 55 PMID:15931571 biolink:Article|biolink:NamedThing|biolink:Publication Brown WM 2001 12 IDrugs Taltirelin (Tanabe Seiyaku). 4 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761035s000lbl.pdf biolink:NamedThing|biolink:Publication 2015 PMID:15306801 biolink:Article|biolink:NamedThing|biolink:Publication Voets T, Droogmans G, Wissenbach U, Janssens A, Flockerzi V, Nilius B 2004 7001 Nature The principle of temperature-dependent gating in cold- and heat-sensitive TRP channels. 430 PMID:18305010 biolink:Article|biolink:NamedThing|biolink:Publication Ehlert FJ, Griffin MT 2008 3 J. Pharmacol. Exp. Ther. Two-state models and the analysis of the allosteric effect of gallamine at the M2 muscarinic receptor. 325 PMID:18258787 biolink:Article|biolink:NamedThing|biolink:Publication Shorter K, Farjo NP, Picksley SM, Randall VA 2008 6 FASEB J. Human hair follicles contain two forms of ATP-sensitive potassium channels, only one of which is sensitive to minoxidil. 22 PMID:8680742 biolink:Article|biolink:NamedThing|biolink:Publication Prior C, Tian L, el Mallah AI, Young L, Ward JM 1995 7 Br. J. Pharmacol. Neuromuscular blocking profile of the vecuronium analogue, Org-9487, in the rat isolated hemidiaphragm preparation. 116 PMID:7551370 biolink:Article|biolink:NamedThing|biolink:Publication Hozawa S, Haruta Y, Ishioka S, Yamakido M 1995 4 Pt 1 Am. J. Respir. Crit. Care Med. Effects of a PAF antagonist, Y-24180, on bronchial hyperresponsiveness in patients with asthma. 152 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf biolink:NamedThing|biolink:Publication 2014 PMID:17705685 biolink:Article|biolink:NamedThing|biolink:Publication Gille A, Bodor ET, Ahmed K, Offermanns S 2008 Annu. Rev. Pharmacol. Toxicol. Nicotinic acid: pharmacological effects and mechanisms of action. 48 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020766s035lbl.pdf biolink:NamedThing|biolink:Publication 2015 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208434s000lbl.pdf biolink:NamedThing|biolink:Publication 2015 PMID:25349307 biolink:Article|biolink:NamedThing|biolink:Publication Kodama T, Tsukaguchi T, Satoh Y, Yoshida M, Watanabe Y, Kondoh O, Sakamoto H 2014 12 Mol. Cancer Ther. Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer. 13 http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020576s010lbl.pdf biolink:NamedThing|biolink:Publication 2010 PMID:26291199 biolink:Article|biolink:NamedThing|biolink:Publication Asaki T, Kuwano K, Morrison K, Gatfield J, Hamamoto T, Clozel M 2015 18 J. Med. Chem. Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension. 58 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207947s000lbl.pdf biolink:NamedThing|biolink:Publication 2015 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207988lbl.pdf biolink:NamedThing|biolink:Publication 2015 PMID:17276408 biolink:Article|biolink:NamedThing|biolink:Publication Triggle DJ 2007 1 Biochem. Pharmacol. Calcium channel antagonists: clinical uses--past, present and future. 74 PMID:10487332 biolink:Article|biolink:NamedThing|biolink:Publication Timmermans PB 1999 2 Hypertens. Res. Angiotensin II receptor antagonists: an emerging new class of cardiovascular therapeutics. 22 PMID:1666418 biolink:Article|biolink:NamedThing|biolink:Publication Kubo M, Ochiai T, Kato J, Ishida R 1991 4 Jpn. J. Pharmacol. Pharmacological studies on TA-6366, a new ACE inhibitor: II. Effect of long-term administration from the pre-hypertensive stage on blood pressure, relative heart weight and ACE activity of various tissues in spontaneously hypertensive rats (SHRs). 57 PMID:22047812 biolink:Article|biolink:NamedThing|biolink:Publication Kim JW, Kim JR, Yi S, Shin KH, Shin HS, Yoon SH, Cho JY, Kim DH, Shin SG, Jang IJ, Yu KS 2011 11 Clin Ther Tolerability and pharmacokinetics of lobeglitazone (CKD-501), a peroxisome proliferator-activated receptor-γ agonist: a single- and multiple-dose, double-blind, randomized control study in healthy male Korean subjects. 33 PMID:8872297 biolink:Article|biolink:NamedThing|biolink:Publication Ziegler D, Haxhiu MA, Kaan EC, Papp JG, Ernsberger P 1996 J. Cardiovasc. Pharmacol. Pharmacology of moxonidine, an I1-imidazoline receptor agonist. 27 Suppl 3 PMID:15716462 biolink:Article|biolink:NamedThing|biolink:Publication Fagart J, Seguin C, Pinon GM, Rafestin-Oblin ME 2005 5 Mol. Pharmacol. The Met852 residue is a key organizer of the ligand-binding cavity of the human mineralocorticoid receptor. 67 PMID:21771637 biolink:Article|biolink:NamedThing|biolink:Publication Kolkhof P, Borden SA 2012 2 Mol. Cell. Endocrinol. Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics. 350 PMID:19833635 biolink:Article|biolink:NamedThing|biolink:Publication Chen YH, Liu CY, Lu JJ, King CH, Hsueh PR 2009 6 J. Antimicrob. Chemother. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan. 64 PMID:12173241 biolink:Article|biolink:NamedThing|biolink:Publication Scholz A 2002 1 Br J Anaesth Mechanisms of (local) anaesthetics on voltage-gated sodium and other ion channels. 89 http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201444s000lbl.pdf biolink:NamedThing|biolink:Publication 2011 PMID:7763301 biolink:Article|biolink:NamedThing|biolink:Publication Coley HM, Brooks N, Phillips DH, Hewer A, Jenkins TC, Jarman M, Judson IR 1995 9 Biochem. Pharmacol. The role of the N-(hydroxymethyl)melamines as antitumour agents: mechanism of action studies. 49 PMID:6200290 biolink:Article|biolink:NamedThing|biolink:Publication Richards DM, Brogden RN, Heel RC, Speight TM, Avery GS 1984 3 Drugs Oxatomide. A review of its pharmacodynamic properties and therapeutic efficacy. 27 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050778s021lbl.pdf biolink:NamedThing|biolink:Publication 2014 http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020645s008lbl.pdf biolink:NamedThing|biolink:Publication 2011 http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019998s013lbl.pdf biolink:NamedThing|biolink:Publication 2007 http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/008922s016lbl.pdf biolink:NamedThing|biolink:Publication 2009 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021749s008lbl.pdf biolink:NamedThing|biolink:Publication 2013 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022252s004lbl.pdf biolink:NamedThing|biolink:Publication 2015 http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-09/mepronizine_ct_8952.pdf biolink:NamedThing|biolink:Publication 2011 PMID:15740719 biolink:Article|biolink:NamedThing|biolink:Publication Gimpl G, Postina R, Fahrenholz F, Reinheimer T 2005 1-2 Eur. J. Pharmacol. Binding domains of the oxytocin receptor for the selective oxytocin receptor antagonist barusiban in comparison to the agonists oxytocin and carbetocin. 510 https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2015-PI-01665-1 biolink:NamedThing|biolink:Publication 2015 PMID:9368911 biolink:Article|biolink:NamedThing|biolink:Publication Bruhwyler J, Liégeois JF, Géczy J 1997 1 Pharmacol. Res. Pirlindole: a selective reversible inhibitor of monoamine oxidase A. A review of its preclinical properties. 36 PMID:12781338 biolink:Article|biolink:NamedThing|biolink:Publication Hynson RM, Wouters J, Ramsay RR 2003 11 Biochem. Pharmacol. Monoamine oxidase A inhibitory potency and flavin perturbation are influenced by different aspects of pirlindole inhibitor structure. 65 PMID:24900486 biolink:Article|biolink:NamedThing|biolink:Publication Rice KD, Aay N, Anand NK, Blazey CM, Bowles OJ, Bussenius J, Costanzo S, Curtis JK, Defina SC, Dubenko L, Engst S, Joshi AA, Kennedy AR, Kim AI, Koltun ES, Lougheed JC, Manalo JC, Martini JF, Nuss JM, Peto CJ, Tsang TH, Yu P, Johnston S 2012 5 ACS Med Chem Lett Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973). 3 PMID:18506437 biolink:Article|biolink:NamedThing|biolink:Publication Sahasranaman S, Howard D, Roy S 2008 8 Eur. J. Clin. Pharmacol. Clinical pharmacology and pharmacogenetics of thiopurines. 64 PMID:26171220 biolink:Article|biolink:NamedThing|biolink:Publication Jain MR, Giri SR, Trivedi C, Bhoi B, Rath A, Vanage G, Vyas P, Ranvir R, Patel PR 2015 3 Pharmacol Res Perspect Saroglitazar, a novel PPARα/γ agonist with predominant PPARα activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models. 3 PMID:17005916 biolink:Article|biolink:NamedThing|biolink:Publication Ligneau X, Perrin D, Landais L, Camelin JC, Calmels TP, Berrebi-Bertrand I, Lecomte JM, Parmentier R, Anaclet C, Lin JS, Bertaina-Anglade V, la Rochelle CD, d'Aniello F, Rouleau A, Gbahou F, Arrang JM, Ganellin CR, Stark H, Schunack W, Schwartz JC 2007 1 J. Pharmacol. Exp. Ther. BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: Preclinical pharmacology. 320 PMID:21615387 biolink:Article|biolink:NamedThing|biolink:Publication Schwartz JC 2011 4 Br. J. Pharmacol. The histamine H3 receptor: from discovery to clinical trials with pitolisant. 163 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125338s085s087s088lbl.pdf biolink:NamedThing|biolink:Publication 2015 http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021877s005lbl.pdf biolink:NamedThing|biolink:Publication 2012 PMID:3207986 biolink:Article|biolink:NamedThing|biolink:Publication Thijssen HH, Baars LG, Vervoort-Peters HT 1988 3 Br. J. Pharmacol. Vitamin K 2,3-epoxide reductase: the basis for stereoselectivity of 4-hydroxycoumarin anticoagulant activity. 95 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207533s000lbl.pdf biolink:NamedThing|biolink:Publication 2015 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/017588s040lbl.pdf biolink:NamedThing|biolink:Publication 2014 PMID:16251241 biolink:Article|biolink:NamedThing|biolink:Publication Wikström B, Gellert R, Ladefoged SD, Danda Y, Akai M, Ide K, Ogasawara M, Kawashima Y, Ueno K, Mori A, Ueno Y 2005 12 J. Am. Soc. Nephrol. Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies. 16 PMID:22084396 biolink:Article|biolink:NamedThing|biolink:Publication Hoeflich KP, Merchant M, Orr C, Chan J, Den Otter D, Berry L, Kasman I, Koeppen H, Rice K, Yang NY, Engst S, Johnston S, Friedman LS, Belvin M 2012 1 Cancer Res. Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition. 72 http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/20706slr011_emadine_lbl.pdf biolink:NamedThing|biolink:Publication 2003 PMID:24660890 biolink:Article|biolink:NamedThing|biolink:Publication Biftu T, Sinha-Roy R, Chen P, Qian X, Feng D, Kuethe JT, Scapin G, Gao YD, Yan Y, Krueger D, Bak A, Eiermann G, He J, Cox J, Hicks J, Lyons K, He H, Salituro G, Tong S, Patel S, Doss G, Petrov A, Wu J, Xu SS, Sewall C, Zhang X, Zhang B, Thornberry NA, Weber AE 2014 8 J. Med. Chem. Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes. 57 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205739s000lbl.pdf biolink:NamedThing|biolink:Publication 2015 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021882s021lbl.pdf biolink:NamedThing|biolink:Publication 2015 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207953s000lbl.pdf biolink:NamedThing|biolink:Publication 2015 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021629s030lbl.pdf biolink:NamedThing|biolink:Publication 2015 PMID:1387020 biolink:Article|biolink:NamedThing|biolink:Publication Yamamura Y, Ogawa H, Yamashita H, Chihara T, Miyamoto H, Nakamura S, Onogawa T, Yamashita T, Hosokawa T, Mori T 1992 4 Br. J. Pharmacol. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. 105 PMID:9469684 biolink:Article|biolink:NamedThing|biolink:Publication Brown LA, Levin GM 1 Pharmacotherapy Sertindole, a new atypical antipsychotic for the treatment of schizophrenia. 18 PMID:10991983 biolink:Article|biolink:NamedThing|biolink:Publication Herrick-Davis K, Grinde E, Teitler M 2000 1 J. Pharmacol. Exp. Ther. Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. 295 PMID:11855658 biolink:Article|biolink:NamedThing|biolink:Publication Endoh M 2001 5 Cardiovasc Drugs Ther Mechanism of action of Ca2+ sensitizers--update 2001. 15 PMID:10644512 biolink:Article|biolink:NamedThing|biolink:Publication Nagumo H, Sasaki Y, Ono Y, Okamoto H, Seto M, Takuwa Y 2000 1 Am. J. Physiol., Cell Physiol. Rho kinase inhibitor HA-1077 prevents Rho-mediated myosin phosphatase inhibition in smooth muscle cells. 278 DOI:10.1016/S0168-8278(14)61094-1 biolink:Article|biolink:NamedThing|biolink:Publication N. Izumi, R. Tateishi, M. Seike, M. Kudo, H. Tamai, S. Kawazoe, K. Tanaka, M. Kurokawa, Y. Osaki, K. Yamamoto, M. Imawari 2014 1 Journal of Hepatology P933 ONCE-DAILY ORAL LUSUTROMBOPAG, ALTERNATIVE TO PLATELET TRANSFUSION IN THROMBOCYTOPENIC PATIENTS WITH CHRONIC LIVER DISEASE UNDERGOING RADIOFREQUENCY ABLATION: RESULTS FROM A PHASE 2B, RANDOMIZED, DOUBLE-BLIND STUDY 60 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125526Orig1s000Lbl.pdf biolink:NamedThing|biolink:Publication 2015 PMID:17652911 biolink:Article|biolink:NamedThing|biolink:Publication Hirata T, Keto Y, Funatsu T, Akuzawa S, Sasamata M 2007 3 J. Pharmacol. Sci. Evaluation of the pharmacological profile of ramosetron, a novel therapeutic agent for irritable bowel syndrome. 104 PMID:19967488 biolink:Article|biolink:NamedThing|biolink:Publication Ayuhara H, Takayanagi R, Okuyama K, Yoshimoto K, Ozeki T, Yokoyama H, Yamada Y 2009 6 Int. J. Clin. Oncol. Receptor occupancy theory-based analysis of interindividual differences in antiemetic effects of 5-HT3 receptor antagonists. 14 PMID:1397053 biolink:Article|biolink:NamedThing|biolink:Publication Boeijinga PH, Galvan M, Baron BM, Dudley MW, Siegel BW, Slone AL 1992 1 Eur. J. Pharmacol. Characterization of the novel 5-HT3 antagonists MDL 73147EF (dolasetron mesilate) and MDL 74156 in NG108-15 neuroblastoma x glioma cells. 219 PMID:25271963 biolink:Article|biolink:NamedThing|biolink:Publication Finlay MR, Anderton M, Ashton S, Ballard P, Bethel PA, Box MR, Bradbury RH, Brown SJ, Butterworth S, Campbell A, Chorley C, Colclough N, Cross DA, Currie GS, Grist M, Hassall L, Hill GB, James D, James M, Kemmitt P, Klinowska T, Lamont G, Lamont SG, Martin N, McFarland HL, Mellor MJ, Orme JP, Perkins D, Perkins P, Richmond G, Smith P, Ward RA, Waring MJ, Whittaker D, Wells S, Wrigley GL 2014 20 J. Med. Chem. Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. 57 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208065s000lbl.pdf biolink:NamedThing|biolink:Publication 2015 PMID:15123680 biolink:Article|biolink:NamedThing|biolink:Publication Fu T, Mukhopadhyay D, Davidson NO, Borensztajn J 2004 27 J. Biol. Chem. The peroxisome proliferator-activated receptor alpha (PPARalpha) agonist ciprofibrate inhibits apolipoprotein B mRNA editing in low density lipoprotein receptor-deficient mice: effects on plasma lipoproteins and the development of atherosclerotic lesions. 279 PMID:9405293 biolink:Article|biolink:NamedThing|biolink:Publication Bowker-Kinley MM, Davis WI, Wu P, Harris RA, Popov KM 1998 Biochem. J. Evidence for existence of tissue-specific regulation of the mammalian pyruvate dehydrogenase complex. 329 ( Pt 1) PMID:1546145 biolink:Article|biolink:NamedThing|biolink:Publication Dingemanse J, Berlin I, Payan C, Thiede HM, Puech AJ 1992 Psychopharmacology (Berl.) Comparative investigation of the effect of moclobemide and toloxatone on monoamine oxidase activity and psychometric performance in healthy subjects. 106 Suppl PMID:12177684 biolink:Article|biolink:NamedThing|biolink:Publication Borsini F, Evans K, Jason K, Rohde F, Alexander B, Pollentier S 2002 2 CNS Drug Rev Pharmacology of flibanserin. 8 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022526lbl.pdf biolink:NamedThing|biolink:Publication 2015 PMID:20840530 biolink:Article|biolink:NamedThing|biolink:Publication Stahl SM, Sommer B, Allers KA 2011 1 J Sex Med Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder. 8 PMID:7878037 biolink:Article|biolink:NamedThing|biolink:Publication Double KL, Crocker AD 1995 5 Proc. Natl. Acad. Sci. U.S.A. Dopamine receptors in the substantia nigra are involved in the regulation of muscle tone. 92 PMID:12480161 biolink:Article|biolink:NamedThing|biolink:Publication Liu YC, Lo YK, Wu SN 2003 1 Brain Res. Stimulatory effects of chlorzoxazone, a centrally acting muscle relaxant, on large conductance calcium-activated potassium channels in pituitary GH3 cells. 959 PMID:16004599 biolink:Article|biolink:NamedThing|biolink:Publication Jenner P 2005 6 Expert Opin Investig Drugs Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease. 14 http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/103694s1008lbl.pdf biolink:NamedThing|biolink:Publication 2009 PMID:20209107 biolink:Article|biolink:NamedThing|biolink:Publication Humbert M, Castéran N, Letard S, Hanssens K, Iovanna J, Finetti P, Bertucci F, Bader T, Mansfield CD, Moussy A, Hermine O, Dubreuil P 2010 3 PLoS ONE Masitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model. 5 http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020572s016,020573s015lbl.pdf biolink:NamedThing|biolink:Publication 2009 http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/09048slr037_methoxsalen_lbl.pdf biolink:NamedThing|biolink:Publication 2003 PMID:11556519 biolink:Article|biolink:NamedThing|biolink:Publication Henrotin Y, de Leval X, Mathy-Hartet M, Mouithys-Mickalad A, Deby-Dupont G, Dogné JM, Delarge J, Reginster JY 2001 8 Inflamm. Res. In vitro effects of aceclofenac and its metabolites on the production by chondrocytes of inflammatory mediators. 50 PMID:22497992 biolink:Article|biolink:NamedThing|biolink:Publication Duffy RA, Morgan C, Naylor R, Higgins GA, Varty GB, Lachowicz JE, Parker EM 2012 1 Pharmacol. Biochem. Behav. Rolapitant (SCH 619734): a potent, selective and orally active neurokinin NK1 receptor antagonist with centrally-mediated antiemetic effects in ferrets. 102 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206500s000lbl.pdf biolink:NamedThing|biolink:Publication 2015 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004004/WC500192715.pdf biolink:NamedThing|biolink:Publication 2015 PMID:2001448 biolink:Article|biolink:NamedThing|biolink:Publication Gasson JC 1991 6 Blood Molecular physiology of granulocyte-macrophage colony-stimulating factor. 77 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125141s219lbl.pdf biolink:NamedThing|biolink:Publication 2014 PMID:22686619 biolink:Article|biolink:NamedThing|biolink:Publication Subramaniam JM, Whiteside G, McKeage K, Croxtall JC 2012 9 Drugs Mogamulizumab: first global approval. 72 http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021665s005lbl.pdf biolink:NamedThing|biolink:Publication 2012 PMID:17234181 biolink:Article|biolink:NamedThing|biolink:Publication Mascia MP, Bachis E, Obili N, Maciocco E, Cocco GA, Sechi GP, Biggio G 2007 1-3 Eur. J. Pharmacol. Thiocolchicoside inhibits the activity of various subtypes of recombinant GABA(A) receptors expressed in Xenopus laevis oocytes. 558 PMID:26056160 biolink:Article|biolink:NamedThing|biolink:Publication Hammer H, Bader BM, Ehnert C, Bundgaard C, Bunch L, Hoestgaard-Jensen K, Schroeder OH, Bastlund JF, Gramowski-Voß A, Jensen AA 2015 2 Mol. Pharmacol. A Multifaceted GABAA Receptor Modulator: Functional Properties and Mechanism of Action of the Sedative-Hypnotic and Recreational Drug Methaqualone (Quaalude). 88 PMID:20093397 biolink:Article|biolink:NamedThing|biolink:Publication Kiss B, Horváth A, Némethy Z, Schmidt E, Laszlovszky I, Bugovics G, Fazekas K, Hornok K, Orosz S, Gyertyán I, Agai-Csongor E, Domány G, Tihanyi K, Adham N, Szombathelyi Z 2010 1 J. Pharmacol. Exp. Ther. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. 333 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204370lbl.pdf biolink:NamedThing|biolink:Publication 2015 PMID:6285914 biolink:Article|biolink:NamedThing|biolink:Publication Rosenfeld RG, Aggarwal BB, Hintz RL, Dollar LA 1982 1 Biochem. Biophys. Res. Commun. Recombinant DNA-derived methionyl human growth hormone is similar in membrane binding properties to human pituitary growth hormone. 106 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207981s000lbl.pdf biolink:NamedThing|biolink:Publication 2015 PMID:8891469 biolink:Article|biolink:NamedThing|biolink:Publication Noble S, McTavish D 1996 4 Drugs Reteplase. A review of its pharmacological properties and clinical efficacy in the management of acute myocardial infarction. 52 http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/19853s012,014lbl.pdf biolink:NamedThing|biolink:Publication 2004 PMID:6121964 biolink:Article|biolink:NamedThing|biolink:Publication Walshe JM 1982 8273 Lancet Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride. 1 PMID:10102460 biolink:Article|biolink:NamedThing|biolink:Publication Eriksson H, Eriksson UG, Frison L, Hansson PO, Held P, Holmström M, Hägg A, Jonsson T, Lapidus L, Leijd B, Stockelberg D, Säfwenberg U, Taghavi A, Thorsén M 1999 3 Thromb. Haemost. Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT. 81 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022037s011lbl.pdf biolink:NamedThing|biolink:Publication 2015 PMID:22633824 biolink:Article|biolink:NamedThing|biolink:Publication Stein EA, Gipe D, Bergeron J, Gaudet D, Weiss R, Dufour R, Wu R, Pordy R 2012 9836 Lancet Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. 380 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/103950s5150lbl.pdf biolink:NamedThing|biolink:Publication 2013 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125559Orig1s000lbl.pdf biolink:NamedThing|biolink:Publication 2015 PMID:9205952 biolink:Article|biolink:NamedThing|biolink:Publication Alvarez-Guerra M, Alda O, Garay RP 1997 6 Naunyn Schmiedebergs Arch. Pharmacol. Celiprolol: agonist and antagonist effects at cardiac beta 1- and vascular beta 2-adrenoceptors determined under in vivo conditions in the rat. 355 http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103979s5135lbl.pdf biolink:NamedThing|biolink:Publication 2010 DOI: biolink:Article|biolink:NamedThing|biolink:Publication CAROPPO, R 1990 1 Curr. Ther. Res.-Clin. Exp. EFFECT OF NIPEROTIDINE ON HYDROGEN-ION SECRETION AND ELECTRICAL PARAMETERS OF ISOLATED ASTRIC-MUCOSA 48 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000369/WC500053612.pdf biolink:NamedThing|biolink:Publication 2015 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204760s000lbl.pdf biolink:NamedThing|biolink:Publication 2014 PMID:22037049 biolink:Article|biolink:NamedThing|biolink:Publication Lewin AH, Miller GM, Gilmour B 2011 23 Bioorg. Med. Chem. Trace amine-associated receptor 1 is a stereoselective binding site for compounds in the amphetamine class. 19 http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/016419s029lbl.pdf biolink:NamedThing|biolink:Publication 2008 PMID:2139412 biolink:Article|biolink:NamedThing|biolink:Publication Santen RJ, Langecker P, Santner SJ, Sikka S, Rajfer J, Swerdloff R 1990 1 Endocr. Res. Potency and specificity of CGS-16949A as an aromatase inhibitor. 16 PMID:2521224 biolink:Article|biolink:NamedThing|biolink:Publication Santen RJ, Demers LM, Adlercreutz H, Harvey H, Santner S, Sanders S, Lipton A 1989 1 J. Clin. Endocrinol. Metab. Inhibition of aromatase with CGS 16949A in postmenopausal women. 68 http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/19385slr030,031,035_permax_lbl.pdf biolink:NamedThing|biolink:Publication 2003 PMID:26131937 biolink:Article|biolink:NamedThing|biolink:Publication Krönke J, Fink EC, Hollenbach PW, MacBeth KJ, Hurst SN, Udeshi ND, Chamberlain PP, Mani DR, Man HW, Gandhi AK, Svinkina T, Schneider RK, McConkey M, Järås M, Griffiths E, Wetzler M, Bullinger L, Cathers BE, Carr SA, Chopra R, Ebert BL 2015 Nature Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207620Orig1s000lbl.pdf biolink:NamedThing|biolink:Publication 2015 PMID:1101049 biolink:Article|biolink:NamedThing|biolink:Publication Youdim MB 1975 Mod Probl Pharmacopsychiatry Monoamine oxidase. Its inhibition. 10 PMID:21186796 biolink:Article|biolink:NamedThing|biolink:Publication Zhang Z, Wallace MB, Feng J, Stafford JA, Skene RJ, Shi L, Lee B, Aertgeerts K, Jennings A, Xu R, Kassel DB, Kaldor SW, Navre M, Webb DR, Gwaltney SL 2011 2 J. Med. Chem. Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV. 54 PMID:26115728 biolink:Article|biolink:NamedThing|biolink:Publication McKeage K 2015 Drugs Trelagliptin: First Global Approval. PMID:11786663 biolink:Article|biolink:NamedThing|biolink:Publication Fukushima Y, Otsuka H, Ishikawa M, Asano T, Anai M, Katsube T, Ogawa K, Kajiwara T, Ohkawa S, Ishikawa T, Omata M, Saitoh T 2001 3 Digestion Potent and long-lasting action of lafutidine on the human histamine H(2) receptor. 64 PMID:7703232 biolink:Article|biolink:NamedThing|biolink:Publication Lotta T, Vidgren J, Tilgmann C, Ulmanen I, Melén K, Julkunen I, Taskinen J 1995 13 Biochemistry Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. 34 PMID:11160603 biolink:Article|biolink:NamedThing|biolink:Publication Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ 2001 2 J. Pharmacol. Exp. Ther. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. 296 PMID:24947465 biolink:Article|biolink:NamedThing|biolink:Publication Maeda K, Sugino H, Akazawa H, Amada N, Shimada J, Futamura T, Yamashita H, Ito N, McQuade RD, Mørk A, Pehrson AL, Hentzer M, Nielsen V, Bundgaard C, Arnt J, Stensbøl TB, Kikuchi T 2014 3 J. Pharmacol. Exp. Ther. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. 350 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205422s000lbl.pdf biolink:NamedThing|biolink:Publication 2015 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021106s036lbl.pdf biolink:NamedThing|biolink:Publication 2013 PMID:20600305 biolink:Article|biolink:NamedThing|biolink:Publication Millan MJ 2010 2 Pharmacol. Ther. From the cell to the clinic: a comparative review of the partial D₂/D₃receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease. 128 PMID:15646370 biolink:Article|biolink:NamedThing|biolink:Publication Doi N, Hirotani C, Ukai K, Shimada O, Okuno T, Kurasaki S, Kiyofuji T, Ikegami R, Futamata M, Nakagawa T, Ase K, Chihara K 2004 12 Arzneimittelforschung Pharmacological characteristics of KP-102 (GHRP-2), a potent growth hormone-releasing peptide. 54 PMID:21668582 biolink:Article|biolink:NamedThing|biolink:Publication Sakata K, Someya M, Matsumoto Y, Tauchi H, Kai M, Toyota M, Takagi M, Hareyama M, Fukushima M 2011 9 Cancer Sci. Gimeracil, an inhibitor of dihydropyrimidine dehydrogenase, inhibits the early step in homologous recombination. 102 PMID:3114201 biolink:Article|biolink:NamedThing|biolink:Publication Tatsumi K, Fukushima M, Shirasaka T, Fujii S 1987 7 Jpn. J. Cancer Res. Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. 78 PMID:8862723 biolink:Article|biolink:NamedThing|biolink:Publication Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M 1996 5 Anticancer Drugs Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. 7 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020637s026lbl.pdf biolink:NamedThing|biolink:Publication 2013 PMID:2858236 biolink:Article|biolink:NamedThing|biolink:Publication Dukes ID, Vaughan Williams EM 1985 2 Br. J. Pharmacol. Cardiovascular effects of bevantolol, a selective beta 1-adrenoceptor antagonist with a novel pharmacological profile. 84 PMID:3924048 biolink:Article|biolink:NamedThing|biolink:Publication Bitonti AJ, Bacchi CJ, McCann PP, Sjoerdsma A 1985 10 Biochem. Pharmacol. Catalytic irreversible inhibition of Trypanosoma brucei brucei ornithine decarboxylase by substrate and product analogs and their effects on murine trypanosomiasis. 34 PMID:21651906 biolink:Article|biolink:NamedThing|biolink:Publication Kawachi M, Matsunaga Y, Tanaka T, Hori Y, Ito K, Nagahama K, Ozaki T, Inoue N, Toda R, Yoshii K, Hirayama M, Kawabata Y, Takei M 2011 1-3 Eur. J. Pharmacol. Acotiamide hydrochloride (Z-338) enhances gastric motility and emptying by inhibiting acetylcholinesterase activity in rats. 666 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022249Orig1s019lbl.pdf biolink:NamedThing|biolink:Publication 2015 PMID:9726653 biolink:Article|biolink:NamedThing|biolink:Publication Fujimoto S, Ohashi M, Hiramoto A, Inoue Y, Nagai K, Shiokawa H, Itoh T 1998 2-3 Eur. J. Pharmacol. Vasorelaxant effect of olprinone, an inhibitor of phosphodiesterase 3, on mesenteric small artery and vein of rabbits. 353 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206334s000lbl.pdf biolink:NamedThing|biolink:Publication 2014 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022011s013lbl.pdf biolink:NamedThing|biolink:Publication 2013 PMID:8723169 biolink:Article|biolink:NamedThing|biolink:Publication Abou-Mohamed G, Nagarajan R, Ibrahim TM, Caldwell RW 1996 1 Cardiovasc Drugs Ther Characterization of the adrenergic activity of arbutamine, a novel agent for pharmacological stress testing. 10 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021476s030lbl.pdf biolink:NamedThing|biolink:Publication 2014 PMID:6114717 biolink:Article|biolink:NamedThing|biolink:Publication Van Wauwe J, Awouters F, Neimegeers CJ, Janssens F, Van Nueten JM, Janssen PA 1981 1 Arch Int Pharmacodyn Ther In vivo pharmacology of astemizole, a new type of H1-antihistaminic compound. 251 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206333Orig1s000lbl.pdf biolink:NamedThing|biolink:Publication 2015 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022575s012lbl.pdf biolink:NamedThing|biolink:Publication 2013 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125427s033lbl.pdf biolink:NamedThing|biolink:Publication 2014 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205123s008lbl.pdf biolink:NamedThing|biolink:Publication 2015 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125103s146lbl.pdf biolink:NamedThing|biolink:Publication 2013 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002556/WC500148380.pdf biolink:NamedThing|biolink:Publication 2015 PMID:23940628 biolink:Article|biolink:NamedThing|biolink:Publication Barrière DA, Mallet C, Blomgren A, Simonsen C, Daulhac L, Libert F, Chapuy E, Etienne M, Högestätt ED, Zygmunt PM, Eschalier A 2013 8 PLoS ONE Fatty acid amide hydrolase-dependent generation of antinociceptive drug metabolites acting on TRPV1 in the brain. 8 PMID:21828261 biolink:Article|biolink:NamedThing|biolink:Publication Shin JM, Inatomi N, Munson K, Strugatsky D, Tokhtaeva E, Vagin O, Sachs G 2011 2 J. Pharmacol. Exp. Ther. Characterization of a novel potassium-competitive acid blocker of the gastric H,K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438). 339 http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/103946s5083lbl.pdf biolink:NamedThing|biolink:Publication 2009 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019627s062lbl.pdf biolink:NamedThing|biolink:Publication 2014 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022393s013lbl.pdf biolink:NamedThing|biolink:Publication 2014 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017808s036lbl.pdf biolink:NamedThing|biolink:Publication 2015 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021999s029lbl.pdf biolink:NamedThing|biolink:Publication 2014 PMID:1696381 biolink:Article|biolink:NamedThing|biolink:Publication Fujii M, Okabayashi Y, Nakamura T, Tani S, Fujisawa T, Otsuki M 1990 4 Pancreas Action of a new cholinergic agonist, aclatonium napadisilate, on isolated rat pancreatic acini. 5 http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/083220s041lbl.pdf biolink:NamedThing|biolink:Publication 2005 http://eisai.jp/medical/products/di/EPI/CSP_C_EPI.pdf biolink:NamedThing|biolink:Publication 2007 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002055/WC500127968.pdf biolink:NamedThing|biolink:Publication 2014 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s028lbl.pdf biolink:NamedThing|biolink:Publication 2015 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021468s019lbl.pdf biolink:NamedThing|biolink:Publication 2014 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021179Orig1s030lbl.pdf biolink:NamedThing|biolink:Publication 2014 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002465/WC500151313.pdf biolink:NamedThing|biolink:Publication 2014 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/017563s023,020222s005lbl.pdf biolink:NamedThing|biolink:Publication 2014 http://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21176lbl.pdf biolink:NamedThing|biolink:Publication 2000 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/203284s001lbl.pdf biolink:NamedThing|biolink:Publication 2014 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021271s006lbl.pdf biolink:NamedThing|biolink:Publication 2014 PMID:11740949 biolink:Article|biolink:NamedThing|biolink:Publication Castelli MP, Mocci I, Sanna AM, Gessa GL, Pani L 2001 2-3 Eur. J. Pharmacol. (-)S amisulpride binds with high affinity to cloned dopamine D(3) and D(2) receptors. 432 PMID:6186851 biolink:Article|biolink:NamedThing|biolink:Publication Levine SN, Hollier B 1 J. Cardiovasc. Pharmacol. Aprindine inhibits calmodulin-stimulated phosphodiesterase and Ca-ATPase activities. 5 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125151s0184lbl.pdf biolink:NamedThing|biolink:Publication 2013 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/103234s5323lbl.pdf biolink:NamedThing|biolink:Publication 2013 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125268s141lbl.pdf biolink:NamedThing|biolink:Publication 2014 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125058s220lbl.pdf biolink:NamedThing|biolink:Publication 2013 http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021959s004lbl.pdf biolink:NamedThing|biolink:Publication 2010 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125460s000lbl.pdf biolink:NamedThing|biolink:Publication 2014 PMID:12825935 biolink:Article|biolink:NamedThing|biolink:Publication Renaud J, Bischoff SF, Buhl T, Floersheim P, Fournier B, Halleux C, Kallen J, Keller H, Schlaeppi JM, Stark W 2003 14 J. Med. Chem. Estrogen receptor modulators: identification and structure-activity relationships of potent ERalpha-selective tetrahydroisoquinoline ligands. 46 PMID:22671931 biolink:Article|biolink:NamedThing|biolink:Publication Wade PR, Palmer JM, McKenney S, Kenigs V, Chevalier K, Moore BA, Mabus JR, Saunders PR, Wallace NH, Schneider CR, Kimball ES, Breslin HJ, He W, Hornby PJ 2012 5 Br. J. Pharmacol. Modulation of gastrointestinal function by MuDelta, a mixed µ opioid receptor agonist/ µ opioid receptor antagonist. 167 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022572s003lbl.pdf biolink:NamedThing|biolink:Publication 2014 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020563s124lbl.pdf biolink:NamedThing|biolink:Publication 2015 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206940s000lbl.pdf biolink:NamedThing|biolink:Publication 2015 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018780s150lbl.pdf biolink:NamedThing|biolink:Publication 2015 PMID:23083772 biolink:Article|biolink:NamedThing|biolink:Publication Dias CS, Shaywitz AJ, Wasserman SM, Smith BP, Gao B, Stolman DS, Crispino CP, Smirnakis KV, Emery MG, Colbert A, Gibbs JP, Retter MW, Cooke BP, Uy ST, Matson M, Stein EA 2012 19 J. Am. Coll. Cardiol. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. 60 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000885/WC500052310.pdf biolink:NamedThing|biolink:Publication 2015 PMID:26518 biolink:Article|biolink:NamedThing|biolink:Publication Galeone M, Moise G, Ferrante F, Cacioli D, Casula PL, Bignamini AA 1978 5 Curr Med Res Opin Double-blind clinical comparison between a gastrin-receptor antagonist, proglumide, and a histamine H2-blocker, cimetidine. 5 PMID:2863192 biolink:Article|biolink:NamedThing|biolink:Publication Loewe CJ, Grider JR, Gardiner J, Vlahcevic ZR 1985 4 Gastroenterology Selective inhibition of pentagastrin- and cholecystokinin-stimulated exocrine secretion by proglumide. 89 PMID:2299627 biolink:Article|biolink:NamedThing|biolink:Publication Freidinger RM, Whitter WL, Gould NP, Holloway MK, Chang RS, Lotti VJ 1990 2 J. Med. Chem. Novel glutamic acid derived cholecystokinin receptor ligands. 33 PMID:28684 biolink:Article|biolink:NamedThing|biolink:Publication Falliers CJ, Redding MA, Katsampes CP 1978 3 Ann Allergy Inhibition of cutaneous and mucosal allergy with phenyltoloxamine. 41 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020718s037lbl.pdf biolink:NamedThing|biolink:Publication 2013 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001012/WC500053998.pdf biolink:NamedThing|biolink:Publication 2014 PMID:17300164 biolink:Article|biolink:NamedThing|biolink:Publication Sturino CF, O'Neill G, Lachance N, Boyd M, Berthelette C, Labelle M, Li L, Roy B, Scheigetz J, Tsou N, Aubin Y, Bateman KP, Chauret N, Day SH, Lévesque JF, Seto C, Silva JH, Trimble LA, Carriere MC, Denis D, Greig G, Kargman S, Lamontagne S, Mathieu MC, Sawyer N, Slipetz D, Abraham WM, Jones T, McAuliffe M, Piechuta H, Nicoll-Griffith DA, Wang Z, Zamboni R, Young RN, Metters KM 2007 4 J. Med. Chem. Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524). 50 PMID:25765567 biolink:Article|biolink:NamedThing|biolink:Publication Nassini R, Fusi C, Materazzi S, Coppi E, Tuccinardi T, Marone IM, De Logu F, Preti D, Tonello R, Chiarugi A, Patacchini R, Geppetti P, Benemei S 2015 Br. J. Pharmacol. The TRPA1 channel mediates the analgesic action of dipyrone and pyrazolone derivatives. PMID:25171227 biolink:Article|biolink:NamedThing|biolink:Publication Sałat K, Jakubowska A, Kulig K 2014 10 Expert Opin Investig Drugs Zucapsaicin for the treatment of neuropathic pain. 23 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125422s025lbl.pdf biolink:NamedThing|biolink:Publication 2014 PMID:14681344 biolink:Article|biolink:NamedThing|biolink:Publication Yu KS, Bae KS, Shon JH, Cho JY, Yi SY, Chung JY, Lim HS, Jang IJ, Shin SG, Song KS, Moon BS 2004 1 J Clin Pharmacol Pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers. 44 PMID:18638004 biolink:Article|biolink:NamedThing|biolink:Publication Paick JS, Ahn TY, Choi HK, Chung WS, Kim JJ, Kim SC, Kim SW, Lee SW, Min KS, Moon KH, Park JK, Park K, Park NC, Suh JK, Yang DY, Jung HG 2008 11 J Sex Med Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction. 5 DOI:10.1002/jlcr.1116 biolink:Article|biolink:NamedThing|biolink:Publication Shin, Hyun-Il; Lee, Juyoung; Kim, Dae-Kee 2006 13 J Labelled Comp Radiopharm. Synthesis of 5-​ethyl-​2-​{5-​[4-​(2-​hydroxyethyl)​piperazin-​1-​ylsulfonyl]​-​2-​n-​propoxyphenyl}​-​7-​n-​propyl-​3,​5-​dihydro-​4H-​pyrrolo[3,​2-​d]​-​[2-​14C]​pyrimidin-​4-​one.2 HCl (14C-​SK3530.2 HCl) 49 PMID:24995399 biolink:Article|biolink:NamedThing|biolink:Publication Song W, Zhang X, Li S, Xu W 2015 3 Chem Biol Drug Des Design, synthesis, and preliminary activity evaluation of novel pyrimidine derivatives as acid pump antagonists. 85 PMID:6422042 biolink:Article|biolink:NamedThing|biolink:Publication Sestanj K, Bellini F, Fung S, Abraham N, Treasurywala A, Humber L, Simard-Duquesne N, Dvornik D 1984 3 J. Med. Chem. N-[5-(trifluoromethyl)-6-methoxy-1-naphthalenyl]thioxomethyl]- N-methylglycine (Tolrestat), a potent, orally active aldose reductase inhibitor. 27 PMID:10766174 biolink:Article|biolink:NamedThing|biolink:Publication Adjei AA, Erlichman C, Davis JN, Cutler DL, Sloan JA, Marks RS, Hanson LJ, Svingen PA, Atherton P, Bishop WR, Kirschmeier P, Kaufmann SH 2000 7 Cancer Res. A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. 60 PMID:8536820 biolink:Article|biolink:NamedThing|biolink:Publication Göke B, Fuder H, Wieckhorst G, Theiss U, Stridde E, Littke T, Kleist P, Arnold R, Lücker PW 1995 6 Digestion Voglibose (AO-128) is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve. 56 PMID:9792651 biolink:Article|biolink:NamedThing|biolink:Publication Cotte N, Balestre MN, Phalipou S, Hibert M, Manning M, Barberis C, Mouillac B 1998 45 J. Biol. Chem. Identification of residues responsible for the selective binding of peptide antagonists and agonists in the V2 vasopressin receptor. 273 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206426lbl.pdf biolink:NamedThing|biolink:Publication 2014 PMID:20530654 biolink:Article|biolink:NamedThing|biolink:Publication Gbahou F, Davenas E, Morisset S, Arrang JM 2010 3 J. Pharmacol. Exp. Ther. Effects of betahistine at histamine H3 receptors: mixed inverse agonism/agonism in vitro and partial inverse agonism in vivo. 334 PMID:7692441 biolink:Article|biolink:NamedThing|biolink:Publication Chen R, Lewis KA, Perrin MH, Vale WW 1993 19 Proc. Natl. Acad. Sci. U.S.A. Expression cloning of a human corticotropin-releasing-factor receptor. 90 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=212 biolink:InformationResource|biolink:NamedThing 2015 PMID:21482695 biolink:Article|biolink:NamedThing|biolink:Publication Rivera VM, Squillace RM, Miller D, Berk L, Wardwell SD, Ning Y, Pollock R, Narasimhan NI, Iuliucci JD, Wang F, Clackson T 2011 6 Mol. Cancer Ther. Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens. 10 PMID:19536319 biolink:Article|biolink:NamedThing|biolink:Publication Ruhlmann C, Herrstedt J 2009 2 Ther Clin Risk Manag Casopitant: a novel NK(1)-receptor antagonist in the prevention of chemotherapy-induced nausea and vomiting. 5 PMID:22805230 biolink:Article|biolink:NamedThing|biolink:Publication Sedehizadeh S, Keogh M, Maddison P 4 Clin Neuropharmacol The use of aminopyridines in neurological disorders. 35 http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202799s001lbl.pdf biolink:NamedThing|biolink:Publication 2012 PMID:23337758 biolink:Article|biolink:NamedThing|biolink:Publication Cheetham P, Petrylak DP 1 Cancer J Tubulin-targeted agents including docetaxel and cabazitaxel. 19 http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=61 biolink:InformationResource|biolink:NamedThing 2015 PMID:1828228 biolink:Article|biolink:NamedThing|biolink:Publication Demicheli C, Albertini JP, Garnier-Suillerot A 1991 2 Eur. J. Biochem. Interaction of mithramycin with DNA. Evidence that mithramycin binds to DNA as a dimer in a right-handed screw conformation. 198 PMID:7527033 biolink:Article|biolink:NamedThing|biolink:Publication Smith BL, Bauer GB, Povirk LF 1994 48 J. Biol. Chem. DNA damage induced by bleomycin, neocarzinostatin, and melphalan in a precisely positioned nucleosome. Asymmetry in protection at the periphery of nucleosome-bound DNA. 269 PMID:11502873 biolink:Article|biolink:NamedThing|biolink:Publication Takasaki J, Kamohara M, Saito T, Matsumoto M, Matsumoto S, Ohishi T, Soga T, Matsushime H, Furuichi K 2001 3 Mol. Pharmacol. Molecular cloning of the platelet P2T(AC) ADP receptor: pharmacological comparison with another ADP receptor, the P2Y(1) receptor. 60 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204958lbl.pdf biolink:NamedThing|biolink:Publication 2015 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001033/WC500043300.pdf biolink:NamedThing|biolink:Publication 2015 http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21022s004lbl.pdf biolink:NamedThing|biolink:Publication 2004 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/012911Orig1s033lbl.pdf biolink:NamedThing|biolink:Publication 2013 PMID:9315536 biolink:Article|biolink:NamedThing|biolink:Publication Phillips DR, Teng W, Arfsten A, Nannizzi-Alaimo L, White MM, Longhurst C, Shattil SJ, Randolph A, Jakubowski JA, Jennings LK, Scarborough RM 1997 5 Circulation Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. 96 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020912s021,020913s018lbl.pdf biolink:NamedThing|biolink:Publication 2015 PMID:1469694 biolink:Article|biolink:NamedThing|biolink:Publication Hartman GD, Egbertson MS, Halczenko W, Laswell WL, Duggan ME, Smith RL, Naylor AM, Manno PD, Lynch RJ, Zhang G 1992 24 J. Med. Chem. Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors. 35 PMID:23063522 biolink:Article|biolink:NamedThing|biolink:Publication Wang J, Mook RA, Lu J, Gooden DM, Ribeiro A, Guo A, Barak LS, Lyerly HK, Chen W 2012 22 Bioorg. Med. Chem. Identification of a novel Smoothened antagonist that potently suppresses Hedgehog signaling. 20 PMID:22042473 biolink:Article|biolink:NamedThing|biolink:Publication Fendrich V, Wiese D, Waldmann J, Lauth M, Heverhagen AE, Rehm J, Bartsch DK 2011 5 Ann. Surg. Hedgehog inhibition with the orally bioavailable Smo antagonist LDE225 represses tumor growth and prolongs survival in a transgenic mouse model of islet cell neoplasms. 254 PMID:21073468 biolink:Article|biolink:NamedThing|biolink:Publication Miller GM 2011 2 J. Neurochem. The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity. 116 PMID:2472386 biolink:Article|biolink:NamedThing|biolink:Publication Bayne ML, Applebaum J, Underwood D, Chicchi GG, Green BG, Hayes NS, Cascieri MA 1989 19 J. Biol. Chem. The C region of human insulin-like growth factor (IGF) I is required for high affinity binding to the type 1 IGF receptor. 264 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021839s016lbl.pdf biolink:NamedThing|biolink:Publication 2014 PMID:21976485 biolink:Article|biolink:NamedThing|biolink:Publication Van Goor F, Hadida S, Grootenhuis PD, Burton B, Stack JH, Straley KS, Decker CJ, Miller M, McCartney J, Olson ER, Wine JJ, Frizzell RA, Ashlock M, Negulescu PA 2011 46 Proc. Natl. Acad. Sci. U.S.A. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. 108 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206038Orig1s000lbl.pdf biolink:NamedThing|biolink:Publication 2015 http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103293s5130lbl.pdf biolink:NamedThing|biolink:Publication 2012 PMID:20030735 biolink:Article|biolink:NamedThing|biolink:Publication Haenisch B, Walstab J, Herberhold S, Bootz F, Tschaikin M, Ramseger R, Bönisch H 2010 6 Fundam Clin Pharmacol Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. 24 PMID:15017615 biolink:Article|biolink:NamedThing|biolink:Publication Atherton C, Jones J, McKaig B, Bebb J, Cunliffe R, Burdsall J, Brough J, Stevenson D, Bonner J, Rordorf C, Scott G, Branson J, Hawkey CJ 2004 2 Clin. Gastroenterol. Hepatol. Pharmacology and gastrointestinal safety of lumiracoxib, a novel cyclooxygenase-2 selective inhibitor: An integrated study. 2 PMID:10794682 biolink:Article|biolink:NamedThing|biolink:Publication Talley JJ, Bertenshaw SR, Brown DL, Carter JS, Graneto MJ, Kellogg MS, Koboldt CM, Yuan J, Zhang YY, Seibert K 2000 9 J. Med. Chem. N-[[(5-methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: A potent and selective inhibitor of COX-2 for parenteral administration. 43 PMID:18060946 biolink:Article|biolink:NamedThing|biolink:Publication Attardi BJ, Zeleznik A, Simhan H, Chiao JP, Mattison DR, Caritis SN 2007 6 Am. J. Obstet. Gynecol. Comparison of progesterone and glucocorticoid receptor binding and stimulation of gene expression by progesterone, 17-alpha hydroxyprogesterone caproate, and related progestins. 197 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021945s005lbl.pdf biolink:NamedThing|biolink:Publication 2013 http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/125031s082lbl.pdf biolink:NamedThing|biolink:Publication 2007 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103353s5184lbl.pdf biolink:NamedThing|biolink:Publication 2015 PMID:20022913 biolink:Article|biolink:NamedThing|biolink:Publication Meyerhof W, Batram C, Kuhn C, Brockhoff A, Chudoba E, Bufe B, Appendino G, Behrens M 2010 2 Chem. Senses The molecular receptive ranges of human TAS2R bitter taste receptors. 35 http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022276s003lbl.pdf biolink:NamedThing|biolink:Publication 2014 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/203568s004lbl.pdf biolink:NamedThing|biolink:Publication 2015 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022264s013s014lbl.pdf biolink:NamedThing|biolink:Publication 2014 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206619s003lbl.pdf biolink:NamedThing|biolink:Publication 2015 http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021756s018lbl.pdf biolink:NamedThing|biolink:Publication 2011 http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125469Orig1s000Lbl.pdf biolink:NamedThing|biolink:Publication 2014 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206143Orig1s000lbl.pdf biolink:NamedThing|biolink:Publication 2015 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/016466s046lbl.pdf biolink:NamedThing|biolink:Publication 2014 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/203214s007lbl.pdf biolink:NamedThing|biolink:Publication 2014 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125496s000lbl.pdf biolink:NamedThing|biolink:Publication 2014 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103795s5548lbl.pdf biolink:NamedThing|biolink:Publication 2015 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103792s5311lbl.pdf biolink:NamedThing|biolink:Publication 2014 http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020261s048,021192s021lbl.pdf biolink:NamedThing|biolink:Publication 2012 http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021174s020lbl.pdf biolink:NamedThing|biolink:Publication 2006 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020986s059s081lbl.pdf biolink:NamedThing|biolink:Publication 2015 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125476s000lbl.pdf biolink:NamedThing|biolink:Publication 2014 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125486_s008lbl.pdf biolink:NamedThing|biolink:Publication 2014 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125019s210s213lbl.pdf biolink:NamedThing|biolink:Publication 2013 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000771/WC500020327.pdf biolink:NamedThing|biolink:Publication 2014 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021536s031s051lbl.pdf biolink:NamedThing|biolink:Publication 2015 PMID:8950316 biolink:Article|biolink:NamedThing|biolink:Publication Uchiyama-Tsuyuki Y, Saitoh M, Muramatsu M 1996 25-26 Life Sci. Identification and characterization of the 5-HT4 receptor in the intestinal tract and striatum of the guinea pig. 59 PMID:8483969 biolink:Article|biolink:NamedThing|biolink:Publication Blandizzi C, Mengozzi G, Intorre L, Natale G, Soldani G, Del Tacca M 1993 4 Pharmacology Inhibitory cholinergic effects of esaprazole on gastric secretion and plasma gastrin levels in the dog. 46 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207103s000lbl.pdf biolink:NamedThing|biolink:Publication 2015 PMID:15542782 biolink:Article|biolink:NamedThing|biolink:Publication Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK, Toogood PL 2004 11 Mol. Cancer Ther. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. 3 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206947s000lbl.pdf biolink:NamedThing|biolink:Publication 2015 PMID:17943726 biolink:Article|biolink:NamedThing|biolink:Publication Matsui J, Yamamoto Y, Funahashi Y, Tsuruoka A, Watanabe T, Wakabayashi T, Uenaka T, Asada M 2008 3 Int. J. Cancer E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. 122 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021912s013lbl.pdf biolink:NamedThing|biolink:Publication 2014 PMID:12090787 biolink:Article|biolink:NamedThing|biolink:Publication Handley DA, Senanayake CH, Dutczak W, Benovic JL, Walle T, Penn RB, Wilkinson HS, Tanoury GJ, Andersson RG, Johansson F, Morley J 2002 2 Pulm Pharmacol Ther Biological actions of formoterol isomers. 15 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205353s000lbl.pdf biolink:NamedThing|biolink:Publication 2015 PMID:23913691 biolink:Article|biolink:NamedThing|biolink:Publication Ehmann DE, Jahic H, Ross PL, Gu RF, Hu J, Durand-Réville TF, Lahiri S, Thresher J, Livchak S, Gao N, Palmer T, Walkup GK, Fisher SL 2013 39 J. Biol. Chem. Kinetics of avibactam inhibition against Class A, C, and D β-lactamases. 288 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000532/WC500040171.pdf biolink:NamedThing|biolink:Publication 2015 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/200603s015lbl.pdf biolink:NamedThing|biolink:Publication 2013 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/011757s103lbl.pdf biolink:NamedThing|biolink:Publication 2014 PMID:25120077 biolink:Article|biolink:NamedThing|biolink:Publication Hida H, Mouri A, Mori K, Matsumoto Y, Seki T, Taniguchi M, Yamada K, Iwamoto K, Ozaki N, Nabeshima T, Noda Y 2015 3 Neuropsychopharmacology Blonanserin ameliorates phencyclidine-induced visual-recognition memory deficits: the complex mechanism of blonanserin action involving D₃-5-HT₂A and D₁-NMDA receptors in the mPFC. 40 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021879s005lbl.pdf biolink:NamedThing|biolink:Publication 2015 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002294/WC500117862.pdf biolink:NamedThing|biolink:Publication 2015 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205776s000lbl.pdf biolink:NamedThing|biolink:Publication 2014 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/20920s033lbl.pdf biolink:NamedThing|biolink:Publication 2013 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125057s367lbl.pdf biolink:NamedThing|biolink:Publication 2014 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021081s062lbl.pdf biolink:NamedThing|biolink:Publication 2015 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002548/WC500182307.pdf biolink:NamedThing|biolink:Publication 2015 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022505s004lbl.pdf biolink:NamedThing|biolink:Publication 2013 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202057s009lbl.pdf biolink:NamedThing|biolink:Publication 2013 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125390s004lbl.pdf biolink:NamedThing|biolink:Publication 2014 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020280s077lbl.pdf biolink:NamedThing|biolink:Publication 2014 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103948s5139lbl.pdf biolink:NamedThing|biolink:Publication 2014 PMID:12482421 biolink:Article|biolink:NamedThing|biolink:Publication Ohwada J, Tsukazaki M, Hayase T, Oikawa N, Isshiki Y, Fukuda H, Mizuguchi E, Sakaitani M, Shiratori Y, Yamazaki T, Ichihara S, Umeda I, Shimma N 2003 2 Bioorg. Med. Chem. Lett. Design, synthesis and antifungal activity of a novel water soluble prodrug of antifungal triazole. 13 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207500Orig1s000lbl.pdf biolink:NamedThing|biolink:Publication 2015 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125516s000lbl.pdf biolink:NamedThing|biolink:Publication 2015 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000773/WC500045832.pdf biolink:NamedThing|biolink:Publication 2014 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125370s053lbl.pdf biolink:NamedThing|biolink:Publication 2014 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/103575s5126lbl.pdf biolink:NamedThing|biolink:Publication 2013 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125326s060lbl.pdf biolink:NamedThing|biolink:Publication 2014 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125319s081lbl.pdf biolink:NamedThing|biolink:Publication 2014 http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/103749s5059lbl.pdf biolink:NamedThing|biolink:Publication 2005 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125084s063lbl.pdf biolink:NamedThing|biolink:Publication 2015 PMID:24936658 biolink:Article|biolink:NamedThing|biolink:Publication Benod C, Villagomez R, Filgueira CS, Hwang PK, Leonard PG, Poncet-Montange G, Rajagopalan S, Fletterick RJ, Gustafsson JÅ, Webb P 2014 6 PLoS ONE The human orphan nuclear receptor tailless (TLX, NR2E1) is druggable. 9 PMID:9112065 biolink:Article|biolink:NamedThing|biolink:Publication Hoogkamer JF, Kleinbloesem CH, Nokhodian A, Ouwerkerk MJ, Lankhaar G, Ungethüm W, Kirch W 1997 6 Eur. J. Clin. Pharmacol. Pharmacokinetics of imidapril and its active metabolite imidaprilat following single dose and during steady state in patients with impaired liver function. 51 PMID:3000389 biolink:Article|biolink:NamedThing|biolink:Publication Takeyama K, Minato H, Fukuya F, Kawahara S, Hosoki K, Kadokawa T 1985 10 Arzneimittelforschung Antihypertensive activity of alacepril, an orally active angiotensin converting enzyme inhibitor, in renal hypertensive rats and dogs. 35 PMID:2419701 biolink:Article|biolink:NamedThing|biolink:Publication Holck M, Fischli W, Hefti F, Gerold M 1986 1 J. Cardiovasc. Pharmacol. Cardiovascular effects of the new angiotensin-converting-enzyme inhibitor, cilazapril, in anesthetized and conscious dogs. 8 PMID:2484083 biolink:Article|biolink:NamedThing|biolink:Publication DeForrest JM, Waldron TL, Krapcho J, Turk C, Rubin B, Powell JR, Cushman DW, Petrillo EW 1989 6 J. Cardiovasc. Pharmacol. Preclinical pharmacology of zofenopril, an inhibitor of angiotensin I converting enzyme. 13 PMID:8427943 biolink:Article|biolink:NamedThing|biolink:Publication Suzuki H, Kawaratani T, Shioya H, Uji Y, Saruta T 1993 1 Biopharm Drug Dispos Study on pharmacokinetics of a new biliary excreted oral angiotensin converting enzyme inhibitor, temocapril (CS-622) in humans. 14 PMID:6782492 biolink:Article|biolink:NamedThing|biolink:Publication Schrör K, Sauerland S, Kuhn A, Rösen R 1980 1 Naunyn Schmiedebergs Arch. Pharmacol. Different sensitivities of prostaglandin-cyclooxygenases in blood platelets and coronary arteries against non-steroidal antiinflammatory drugs. 313 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125147s200lbl.pdf biolink:NamedThing|biolink:Publication 2015 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125085s305lbl.pdf biolink:NamedThing|biolink:Publication 2014 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125409s104lbl.pdf biolink:NamedThing|biolink:Publication 2015 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125377s055lbl.pdf biolink:NamedThing|biolink:Publication 2015 http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125075s130lbl.pdf biolink:NamedThing|biolink:Publication 2009 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002498/WC500138940.pdf biolink:NamedThing|biolink:Publication 2015 http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125349s000lbl.pdf biolink:NamedThing|biolink:Publication 2012 DOI:10.1111/j.1527-3458.1998.tb00067.x biolink:Article|biolink:NamedThing|biolink:Publication Kojima, Jun; Onodera, Kenji; Ozeki, Mitsuo; Nakayama, Kunio 1998 3 CNS Drug Reviews Ipidacrine (NIK-247): A Review of Multiple Mechanisms as an Antidementia Agent 4 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206162lbl.pdf biolink:NamedThing|biolink:Publication 2014 PMID:9530547 biolink:Article|biolink:NamedThing|biolink:Publication Gunasekara NS, Faulds D 1998 3 Drugs Raltitrexed. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. 55 PMID:11431468 biolink:Article|biolink:NamedThing|biolink:Publication Chao SH, Price DH 2001 34 J. Biol. Chem. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. 276 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125388_S056S078lbl.pdf biolink:NamedThing|biolink:Publication 2014 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125320s170lbl.pdf biolink:NamedThing|biolink:Publication 2015 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125261s114lbl.pdf biolink:NamedThing|biolink:Publication 2014 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125289s094lbl.pdf biolink:NamedThing|biolink:Publication 2013 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125160s215lbl.pdf biolink:NamedThing|biolink:Publication 2013 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125166s368s380lbl.pdf biolink:NamedThing|biolink:Publication 2014 isbn:0071624422 biolink:Book|biolink:NamedThing|biolink:Publication Laurence L. Brunton & Bruce A. Chabner & Bjorn C. Knollmann 2011 Goodman and Gilman's The Pharmacological Basis of Therapeutics http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000666/WC500021287.pdf biolink:NamedThing|biolink:Publication 2009 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125104s840s847s889lbl.pdf biolink:NamedThing|biolink:Publication 2013 PMID:15869320 biolink:Article|biolink:NamedThing|biolink:Publication 2005 3 Drugs R D Cilansetron: KC 9946. 6 http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202292s000lbl.pdf biolink:NamedThing|biolink:Publication 2012 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125156s106lbl.pdf biolink:NamedThing|biolink:Publication 2015 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103976s5161lbl.pdf biolink:NamedThing|biolink:Publication 2014 PMID:18974361 biolink:Article|biolink:NamedThing|biolink:Publication Perez-Reyes E, Van Deusen AL, Vitko I 2009 2 J. Pharmacol. Exp. Ther. Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. 328 PMID:1281221 biolink:Article|biolink:NamedThing|biolink:Publication Cohen CJ, Spires S, Van Skiver D 1992 4 J. Gen. Physiol. Block of T-type Ca channels in guinea pig atrial cells by antiarrhythmic agents and Ca channel antagonists. 100 PMID:18306243 biolink:Article|biolink:NamedThing|biolink:Publication LeWitt PA, Guttman M, Tetrud JW, Tuite PJ, Mori A, Chaikin P, Sussman NM 2008 3 Ann. Neurol. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). 63 PMID:17616698 biolink:Article|biolink:NamedThing|biolink:Publication Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN, Jiang J, Laidig GJ, Lewis ER, Parlati F, Shenk KD, Smyth MS, Sun CM, Vallone MK, Woo TM, Molineaux CJ, Bennett MK 2007 13 Cancer Res. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. 67 PMID:22080169 biolink:Article|biolink:NamedThing|biolink:Publication Ning ZQ, Li ZB, Newman MJ, Shan S, Wang XH, Pan DS, Zhang J, Dong M, Du X, Lu XP 2012 4 Cancer Chemother. Pharmacol. Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. 69 PMID:11309480 biolink:Article|biolink:NamedThing|biolink:Publication Snyder JP, Nettles JH, Cornett B, Downing KH, Nogales E 2001 9 Proc. Natl. Acad. Sci. U.S.A. The binding conformation of Taxol in beta-tubulin: a model based on electron crystallographic density. 98 PMID:19010832 biolink:Article|biolink:NamedThing|biolink:Publication Morris PG, Fornier MN 2008 22 Clin. Cancer Res. Microtubule active agents: beyond the taxane frontier. 14 PMID:21466810 biolink:Article|biolink:NamedThing|biolink:Publication Inayoshi A, Sugimoto Y, Funahashi J, Takahashi S, Matsubara M, Kusaka H 2011 19-20 Life Sci. Mechanism underlying the block of human Cav3.2 T-type Ca2+ channels by benidipine, a dihydropyridine Ca2+ channel blocker. 88 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103772s5370lbl.pdf biolink:NamedThing|biolink:Publication 2015 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103705s5432lbl.pdf biolink:NamedThing|biolink:Publication 2014 PMID:1717223 biolink:Article|biolink:NamedThing|biolink:Publication 1991 2 Drugs Roxatidine acetate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic potential in peptic ulcer disease and related disorders 42 PMID:24558448 biolink:Article|biolink:NamedThing|biolink:Publication 2014 2 PLoS ONE Long-term activation upon brief exposure to xanomleline is unique to M1 and M4 subtypes of muscarinic acetylcholine receptors 9 PMID:16274260 biolink:Article|biolink:NamedThing|biolink:Publication 2005 6 Drugs R D Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist: receptor selectivity and in vitro antihistaminic activity 6 PMID:1620298 biolink:Article|biolink:NamedThing|biolink:Publication 1992 3 Neurosurgery Therapeutic trial of cerebral vasospasm with the serine protease inhibitor, FUT-175, administered in the acute stage after subarachnoid hemorrhage 30 PMID:1983712 biolink:Article|biolink:NamedThing|biolink:Publication 1990 5 Ital J Gastroenterol The effect of the H2-antagonist niperotidine on intragastric acidity in healthy subjects undergoing 24-hour pH-monitoring 22 PMID:21709094 biolink:Article|biolink:NamedThing|biolink:Publication 2011 9 Antimicrob. Agents Chemother. In vitro spectrum of activity of finafloxacin, a novel, pH-activated fluoroquinolone, under standard and acidic conditions 55 http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2009/10/WC500005871.pdf biolink:NamedThing|biolink:Publication 2008 PMID:10878285 biolink:Article|biolink:NamedThing|biolink:Publication Allison AC, Eugui EM 2000 2-3 Immunopharmacology Mycophenolate mofetil and its mechanisms of action. 47 PMID:17915852 biolink:Article|biolink:NamedThing|biolink:Publication Binda C, Wang J, Pisani L, Caccia C, Carotti A, Salvati P, Edmondson DE, Mattevi A 2007 23 J. Med. Chem. Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. 50 PMID:17030736 biolink:Article|biolink:NamedThing|biolink:Publication Caccia C, Maj R, Calabresi M, Maestroni S, Faravelli L, Curatolo L, Salvati P, Fariello RG 2006 7 Suppl 2 Neurology Safinamide: from molecular targets to a new anti-Parkinson drug. 67 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022275s014lbl.pdf biolink:NamedThing|biolink:Publication 2014 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000679/WC500037902.pdf biolink:NamedThing|biolink:Publication 2011 PMID:24872026 biolink:Article|biolink:NamedThing|biolink:Publication Wang C, Thudium KB, Han M, Wang XT, Huang H, Feingersh D, Garcia C, Wu Y, Kuhne M, Srinivasan M, Singh S, Wong S, Garner N, Leblanc H, Bunch RT, Blanset D, Selby MJ, Korman AJ 2014 9 Cancer Immunol Res In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. 2 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002430/WC500133771.pdf biolink:NamedThing|biolink:Publication 2012 PMID:14599363 biolink:Article|biolink:NamedThing|biolink:Publication Witte DG, Cassar SC, Masters JN, Esbenshade T, Hancock AA 2002 5 J Biomol Screen Use of a fluorescent imaging plate reader--based calcium assay to assess pharmacological differences between the human and rat vanilloid receptor. 7 http://www.hsc.nihr.ac.uk/files/downloads/2226/2524.a929981f.Zucapsaicin_Nov13.pdf biolink:InformationResource|biolink:NamedThing 2013 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125514lbl.pdf biolink:NamedThing|biolink:Publication 2014 http://www.pmda.go.jp/english/service/pdf/drugs/remitch_jan2009_e.pdf biolink:NamedThing|biolink:Publication 2009 PMID:17071817 biolink:Article|biolink:NamedThing|biolink:Publication Su S, Ohno Y, Lossin C, Hibino H, Inanobe A, Kurachi Y 2007 2 J. Pharmacol. Exp. Ther. Inhibition of astroglial inwardly rectifying Kir4.1 channels by a tricyclic antidepressant, nortriptyline. 320 http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022036lbl.pdf biolink:NamedThing|biolink:Publication 2010 PMID:2445740 biolink:Article|biolink:NamedThing|biolink:Publication Schmid-Antomarchi H, De Weille J, Fosset M, Lazdunski M 1987 33 J. Biol. Chem. The receptor for antidiabetic sulfonylureas controls the activity of the ATP-modulated K+ channel in insulin-secreting cells. 262 PMID:21486038 biolink:Article|biolink:NamedThing|biolink:Publication Bang-Andersen B, Ruhland T, Jørgensen M, Smith G, Frederiksen K, Jensen KG, Zhong H, Nielsen SM, Hogg S, Mørk A, Stensbøl TB 2011 9 J. Med. Chem. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. 54 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204447s004lbl.pdf biolink:NamedThing|biolink:Publication 2014 PMID:15322733 biolink:Article|biolink:NamedThing|biolink:Publication Knight AR, Misra A, Quirk K, Benwell K, Revell D, Kennett G, Bickerdike M 2004 2 Naunyn Schmiedebergs Arch. Pharmacol. Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. 370 PMID:11716850 biolink:Article|biolink:NamedThing|biolink:Publication Sunaga Y, Gonoi T, Shibasaki T, Ichikawa K, Kusama H, Yano H, Seino S 2001 1 Eur. J. Pharmacol. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide. 431 PMID:10742287 biolink:Article|biolink:NamedThing|biolink:Publication Gopalakrishnan M, Molinari EJ, Shieh CC, Monteggia LM, Roch JM, Whiteaker KL, Scott VE, Sullivan JP, Brioni JD 2000 7 Br. J. Pharmacol. Pharmacology of human sulphonylurea receptor SUR1 and inward rectifier K(+) channel Kir6.2 combination expressed in HEK-293 cells. 129 http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103691s5095lbl.pdf biolink:NamedThing|biolink:Publication 2011 http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020807s011lbl.pdf biolink:NamedThing|biolink:Publication 2006 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125277s071lbl.pdf biolink:NamedThing|biolink:Publication 2014 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125431s000lbl.pdf biolink:NamedThing|biolink:Publication 2014 PMID:15331566 biolink:Article|biolink:NamedThing|biolink:Publication Baggio LL, Huang Q, Brown TJ, Drucker DJ 2004 9 Diabetes A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. 53 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021289s019lbl.pdf biolink:NamedThing|biolink:Publication 2014 http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21322lbl.pdf biolink:NamedThing|biolink:Publication 2004 http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/20367s066lbl.pdf biolink:NamedThing|biolink:Publication 2005 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125276s092lbl.pdf biolink:NamedThing|biolink:Publication 2013 PMID:23253932 biolink:Article|biolink:NamedThing|biolink:Publication Patel DD, Lee DM, Kolbinger F, Antoni C 2013 Ann. Rheum. Dis. Effect of IL-17A blockade with secukinumab in autoimmune diseases. 72 Suppl 2 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103770s5185lbl.pdf biolink:NamedThing|biolink:Publication 2014 PMID:16399882 biolink:Article|biolink:NamedThing|biolink:Publication Petroski RE, Pomeroy JE, Das R, Bowman H, Yang W, Chen AP, Foster AC 2006 1 J. Pharmacol. Exp. Ther. Indiplon is a high-affinity positive allosteric modulator with selectivity for alpha1 subunit-containing GABAA receptors. 317 PMID:11755161 biolink:Article|biolink:NamedThing|biolink:Publication Noguchi H, Kitazumi K, Mori M, Shiba T 2002 1-2 Eur. J. Pharmacol. Binding and neuropharmacological profile of zaleplon, a novel nonbenzodiazepine sedative/hypnotic. 434 PMID:23279183 biolink:Article|biolink:NamedThing|biolink:Publication Kitagawa D, Yokota K, Gouda M, Narumi Y, Ohmoto H, Nishiwaki E, Akita K, Kirii Y 2013 2 Genes Cells Activity-based kinase profiling of approved tyrosine kinase inhibitors. 18 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021938s027lbl.pdf biolink:NamedThing|biolink:Publication 2014 PMID:21575866 biolink:Article|biolink:NamedThing|biolink:Publication Sakamoto H, Tsukaguchi T, Hiroshima S, Kodama T, Kobayashi T, Fukami TA, Oikawa N, Tsukuda T, Ishii N, Aoki Y 2011 5 Cancer Cell CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. 19 PMID:20163176 biolink:Article|biolink:NamedThing|biolink:Publication McCauley JA, McIntyre CJ, Rudd MT, Nguyen KT, Romano JJ, Butcher JW, Gilbert KF, Bush KJ, Holloway MK, Swestock J, Wan BL, Carroll SS, DiMuzio JM, Graham DJ, Ludmerer SW, Mao SS, Stahlhut MW, Fandozzi CM, Trainor N, Olsen DB, Vacca JP, Liverton NJ 2010 6 J. Med. Chem. Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor. 53 GOOGLE_PATENT:US20080064681A1 biolink:NamedThing 2008 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003906/WC500181492.pdf biolink:NamedThing|biolink:Publication 2015 PMID:18672868 biolink:Article|biolink:NamedThing|biolink:Publication Pinto-Bazurco Mendieta MA, Negri M, Jagusch C, Müller-Vieira U, Lauterbach T, Hartmann RW 2008 16 J. Med. Chem. Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer. 51 http://www.accessdata.fda.gov/drugsatfda_docs/label/2001/basnova032301LB.pdf biolink:NamedThing|biolink:Publication 2001 PMID:12191614 biolink:Article|biolink:NamedThing|biolink:Publication Sasaki Y, Suzuki M, Hidaka H 2002 2-3 Pharmacol. Ther. The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway. 93 PMID:25414122 biolink:Article|biolink:NamedThing|biolink:Publication Garnock-Jones KP 2014 18 Drugs Ripasudil: first global approval. 74 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125511s000lbl.pdf biolink:NamedThing|biolink:Publication 2015 PMID:11830761 biolink:Article|biolink:NamedThing|biolink:Publication Lapin I 2001 4 CNS Drug Rev Phenibut (beta-phenyl-GABA): a tranquilizer and nootropic drug. 7 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020788s024lbl.pdf biolink:NamedThing|biolink:Publication 2014 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125418s020lbl.pdf biolink:NamedThing|biolink:Publication 2013 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000916/WC500038317.pdf biolink:NamedThing|biolink:Publication 2014 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019810s098,022056s014lbl.pdf biolink:NamedThing|biolink:Publication 2014 PMID:9520489 biolink:Article|biolink:NamedThing|biolink:Publication Nemeth EF, Steffey ME, Hammerland LG, Hung BC, Van Wagenen BC, DelMar EG, Balandrin MF 1998 7 Proc. Natl. Acad. Sci. U.S.A. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. 95 PMID:15200144 biolink:Article|biolink:NamedThing|biolink:Publication Breitwieser GE, Miedlich SU, Zhang M 2004 3 Cell Calcium Calcium sensing receptors as integrators of multiple metabolic signals. 35 PMID:19751980 biolink:Article|biolink:NamedThing|biolink:Publication Aurelio L, Valant C, Figler H, Flynn BL, Linden J, Sexton PM, Christopoulos A, Scammells PJ 2009 20 Bioorg. Med. Chem. 3- and 6-Substituted 2-amino-4,5,6,7-tetrahydrothieno[2,3-c]pyridines as A1 adenosine receptor allosteric modulators and antagonists. 17 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125477s007lbl.pdf biolink:NamedThing|biolink:Publication 2014 PMID:24169554 biolink:Article|biolink:NamedThing|biolink:Publication Gingell JJ, Burns ER, Hay DL 2014 1 Endocrinology Activity of pramlintide, rat and human amylin but not Aβ1-42 at human amylin receptors. 155 isbn:0853699143 biolink:Book|biolink:NamedThing|biolink:Publication Karen Baxter 2010 Stockley's Drug Interactions http://www.cancer.gov/cancertopics/cancerlibrary/terminologyresources/fmt biolink:InformationResource|biolink:NamedThing http://www.lexi.com biolink:InformationResource|biolink:NamedThing PMID:19661462 biolink:Article|biolink:NamedThing|biolink:Publication 2009 Circ Res Using lidocaine and benzocaine to link sodium channel molecular conformations to state-dependent antiarrhythmic drug affinity. PMID:18500680 biolink:Article|biolink:NamedThing|biolink:Publication 2008 Horm Metab Res Cetilistat (ATL-962), a novel pancreatic lipase inhibitor, ameliorates body weight gain and improves lipid profiles in rats. PMID:19428599 biolink:Article|biolink:NamedThing|biolink:Publication 2009 Antiviral Res T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. PMID:19783139 biolink:Article|biolink:NamedThing|biolink:Publication 2009 Bioorg Med Chem Lett Discovery of 3-(2-cyano-4-pyridyl)-5-(4-pyridyl)-1,2,4-triazole, FYX-051 - a xanthine oxidoreductase inhibitor for the treatment of hyperuricemia [corrected]. PMID:22139434 biolink:Article|biolink:NamedThing|biolink:Publication 2012 Naunyn Schmiedebergs Arch Pharmacol Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. PMID:20302302 biolink:Article|biolink:NamedThing|biolink:Publication 2010 J Med Chem (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucito l (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment. PMID:22889351 biolink:Article|biolink:NamedThing|biolink:Publication 2012 J Med Chem Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. PMID:12519058 biolink:Article|biolink:NamedThing|biolink:Publication 2003 J Med Chem Potential tumor-selective nitroimidazolylmethyluracil prodrug derivatives: inhibitors of the angiogenic enzyme thymidine phosphorylase. PMID:22959556 biolink:Article|biolink:NamedThing|biolink:Publication 2012 Bioorg Med Chem Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-y lcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. PMID:20959606 biolink:Article|biolink:NamedThing|biolink:Publication 2011 Blood CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. PMID:22019046 biolink:Article|biolink:NamedThing|biolink:Publication 2011 Bioorg Med Chem Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methyl pyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor. PMID:20863829 biolink:Article|biolink:NamedThing|biolink:Publication 2010 Eur J Pharmacol Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. PMID:20565075 biolink:Article|biolink:NamedThing|biolink:Publication 2010 J Med Chem Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H -1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia. PMID:25043012 biolink:Article|biolink:NamedThing|biolink:Publication 2014 Nature Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. PMID:21502615 biolink:Article|biolink:NamedThing|biolink:Publication 2011 Antimicrob Agents Chemother In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model. PMID:11302816 biolink:Article|biolink:NamedThing|biolink:Publication 2001 Antimicrob Agents Chemother In vitro antifungal activity of KP-103, a novel triazole derivative, and its therapeutic efficacy against experimental plantar tinea pedis and cutaneous candidiasis in guinea pigs. PMID:20410884 biolink:Article|biolink:NamedThing|biolink:Publication 2010 Nature Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. PMID:17293563 biolink:Article|biolink:NamedThing|biolink:Publication 2007 J Pharmacol Exp Ther Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. PMID:23742252 biolink:Article|biolink:NamedThing|biolink:Publication 2013 J Med Chem Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulf onyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. PMID:18447380 biolink:Article|biolink:NamedThing|biolink:Publication 2008 J Med Chem Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. PMID:22058426 biolink:Article|biolink:NamedThing|biolink:Publication 2012 J Lipid Res Property-based design of a glucosylceramide synthase inhibitor that reduces glucosylceramide in the brain. PMID:23499664 biolink:Article|biolink:NamedThing|biolink:Publication 2013 Neuropharmacology Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety. PMID:19256507 biolink:Article|biolink:NamedThing|biolink:Publication 2009 J Med Chem Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihy dro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor. PMID:21985634 biolink:Article|biolink:NamedThing|biolink:Publication 2012 Diabetes Obes Metab Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. PMID:2164086 biolink:Article|biolink:NamedThing|biolink:Publication 1990 J Pharmacol Exp Ther BY 1023/SK&F 96022 INN pantoprazole, a novel gastric proton pump inhibitor, potently inhibits acid secretion but lacks relevant cytochrome P450 interactions. PMID:10454045 biolink:Article|biolink:NamedThing|biolink:Publication 1999 J Pharm Pharmacol [3H]AL-5848 ([3H]9beta-(+)-Fluprostenol). Carboxylic acid of travoprost (AL-6221), a novel FP prostaglandin to study the pharmacology and autoradiographic localization of the FP receptor. PMID:22640220 biolink:Article|biolink:NamedThing|biolink:Publication 2012 Cent Nerv Syst Agents Med Chem Melatonin and synthetic melatonergic agonists: actions and metabolism in the central nervous system. PMID:20371707 biolink:Article|biolink:NamedThing|biolink:Publication 2010 J Pharmacol Exp Ther Pharmacological characterization of olodaterol, a novel inhaled beta2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models. PMID:18417092 biolink:Article|biolink:NamedThing|biolink:Publication 2008 Ann Endocrinol (Paris) Preclinical pharmacology of the new GLP-1 receptor agonist AVE0010. PMID:19317446 biolink:Article|biolink:NamedThing|biolink:Publication 2009 J Med Chem Discovery of novel 1-azoniabicyclo[2.2.2]octane muscarinic acetylcholine receptor antagonists. PMID:22171087 biolink:Article|biolink:NamedThing|biolink:Publication 2012 J Pharmacol Exp Ther Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. PMID:19263460 biolink:Article|biolink:NamedThing|biolink:Publication 2009 ChemMedChem Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. PMID:11256231 biolink:Article|biolink:NamedThing|biolink:Publication 2000 Methods Find Exp Clin Pharmacol Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro. PMID:22862294 biolink:Article|biolink:NamedThing|biolink:Publication 2012 J Med Chem The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-p ropylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist. PMID:17154430 biolink:Article|biolink:NamedThing|biolink:Publication 2007 ChemMedChem Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. PMID:20845908 biolink:Article|biolink:NamedThing|biolink:Publication 2010 J Med Chem Discovery of a beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. PMID:18678486 biolink:Article|biolink:NamedThing|biolink:Publication 2008 Bioorg Med Chem Lett Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350. PMID:10461840 biolink:Article|biolink:NamedThing|biolink:Publication 1999 Int J Antimicrob Agents Efficacy of NND-502, a novel imidazole antimycotic agent, in experimental models of Candida albicans and Aspergillus fumigatus infections. PMID:9559824 biolink:Article|biolink:NamedThing|biolink:Publication 1998 Antimicrob Agents Chemother In vitro and in vivo antidermatophyte activities of NND-502, a novel optically active imidazole antimycotic agent. PMID:12939461 biolink:Article|biolink:NamedThing|biolink:Publication 2003 Mol Cancer Ther Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. PMID:17588934 biolink:Article|biolink:NamedThing|biolink:Publication 2007 Science An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site. PMID:23601816 biolink:Article|biolink:NamedThing|biolink:Publication 2013 Bioorg Med Chem Synthesis and biological evaluation of Esaprazole analogues showing sigma1 binding and neuroprotective properties in vitro. PMID:20503967 biolink:Article|biolink:NamedThing|biolink:Publication 2010 J Med Chem Factor Xa inhibitors: next-generation antithrombotic agents. PMID:16332435 biolink:Article|biolink:NamedThing|biolink:Publication 2006 Bioorg Med Chem Lett Design and synthesis of a novel, achiral class of highly potent and selective, orally active neurokinin-1 receptor antagonists. PMID:24320933 biolink:Article|biolink:NamedThing|biolink:Publication 2014 J Med Chem Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. PMID:18232657 biolink:Article|biolink:NamedThing|biolink:Publication 2008 J Med Chem Lipophilic modifications to dinucleoside polyphosphates and nucleotides that confer antagonist properties at the platelet P2Y12 receptor. PMID:17872968 biolink:Article|biolink:NamedThing|biolink:Publication 2007 Mol Pharmacol The molecular basis of high-affinity binding of the antiarrhythmic compound vernakalant (RSD1235) to Kv1.5 channels. PMID:10428387 biolink:Article|biolink:NamedThing|biolink:Publication 1999 Bioorg Med Chem Synthesis and antimuscarinic activity of a series of 4-(1-Imidazolyl)-2,2-diphenylbutyramides: discovery of potent and subtype-selective antimuscarinic agents. PMID:19522465 biolink:Article|biolink:NamedThing|biolink:Publication 2009 J Med Chem Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120). PMID:18570382 biolink:Article|biolink:NamedThing|biolink:Publication 2008 Biochemistry Defining the binding site of levosimendan and its analogues in a regulatory cardiac troponin C-troponin I complex. PMID:22264484 biolink:Article|biolink:NamedThing|biolink:Publication 2012 Bioorg Med Chem Lett Synthesis and antihypertensive activity of pyrimidin-4(3H)-one derivatives as losartan analogue for new angiotensin II receptor type 1 (AT1) antagonists. PMID:20590641 biolink:Article|biolink:NamedThing|biolink:Publication 2010 Br J Pharmacol Molecular determinants of state-dependent block of voltage-gated sodium channels by pilsicainide. PMID:18800822 biolink:Article|biolink:NamedThing|biolink:Publication 2008 J Med Chem 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin- 1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. PMID:22869577 biolink:Article|biolink:NamedThing|biolink:Publication 2012 Antimicrob Agents Chemother Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032). PMID:1830563 biolink:Article|biolink:NamedThing|biolink:Publication 1991 Hypertension Ro 42-5892 is a potent orally active renin inhibitor in primates. PMID:18299583 biolink:Article|biolink:NamedThing|biolink:Publication 2008 Proc Natl Acad Sci U S A Pharmacological disruption of calcium channel trafficking by the alpha2delta ligand gabapentin. PMID:21651903 biolink:Article|biolink:NamedThing|biolink:Publication 2011 Eur J Pharmacol Pregabalin is a potent and selective ligand for alpha(2)delta-1 and alpha(2)delta-2 calcium channel subunits. PMID:8839659 biolink:Article|biolink:NamedThing|biolink:Publication 1996 Eur J Clin Pharmacol Antimuscarinic effect of tiquizium bromide in vitro and in vivo. PMID:24508831 biolink:Article|biolink:NamedThing|biolink:Publication 2014 Eur J Med Chem Synthesis, biological evaluation and molecular modeling study of novel tacrine-carbazole hybrids as potential multifunctional agents for the treatment of Alzheimer's disease. PMID:2851680 biolink:Article|biolink:NamedThing|biolink:Publication 1988 Jpn J Pharmacol Pharmacological profiles of CS-622, a novel angiotensin converting enzyme inhibitor. PMID:3021350 biolink:Article|biolink:NamedThing|biolink:Publication 1986 Chem Pharm Bull (Tokyo) Design and synthesis of N-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L -alanyl]-N-(indan-2-yl)glycine (CV-3317), a new, potent angiotensin converting enzyme inhibitor. PMID:8891872 biolink:Article|biolink:NamedThing|biolink:Publication 1996 J Cardiovasc Pharmacol Affinity of angiotensin I-converting enzyme (ACE) inhibitors for N- and C-binding sites of human ACE is different in heart, lung, arteries, and veins. PMID:12510841 biolink:Article|biolink:NamedThing|biolink:Publication 2002 Arch Pharm Res Mechanism of erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159. PMID:10976457 biolink:Article|biolink:NamedThing|biolink:Publication 2000 Nihon Yakurigaku Zasshi [Pharmacological properties of naftopidil, a drug for treatment of the bladder outlet obstruction for patients with benign prostatic hyperplasia]. PMID:2572952 biolink:Article|biolink:NamedThing|biolink:Publication 1989 Life Sci The partial opiate receptor agonists, dezocine and ciramadol act as mu receptor antagonists at the feline ileocecal sphincter. PMID:19153939 biolink:Article|biolink:NamedThing|biolink:Publication 2009 Pharmacopsychiatry A randomized, open-label trial comparing methadone and Levo-Alpha-Acetylmethadol (LAAM) in maintenance treatment of opioid addiction. PMID:5224878 biolink:Article|biolink:NamedThing|biolink:Publication 1966 Odontol Revy Octapressin as a vasoconstrictor in dental plexus anesthesia. PMID:17179482 biolink:Article|biolink:NamedThing|biolink:Publication 2006 J Natl Cancer Inst Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models. PMID:21669536 biolink:Article|biolink:NamedThing|biolink:Publication 2011 Bioorg Med Chem Mapping the intestinal alpha-glucogenic enzyme specificities of starch digesting maltase-glucoamylase and sucrase-isomaltase. PMID:17275317 biolink:Article|biolink:NamedThing|biolink:Publication 2007 Bioorg Med Chem Synthesis and structure-activity relationships of novel warfarin derivatives. PMID:6148400 biolink:Article|biolink:NamedThing|biolink:Publication 1984 J Pharm Pharmacol Determination of biological activity of adinazolam and its metabolites. PMID:10720420 biolink:Article|biolink:NamedThing|biolink:Publication 2000 Circ Res The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. PMID:1775162 biolink:Article|biolink:NamedThing|biolink:Publication 1991 Mol Biochem Parasitol Artemisinin (qinghaosu): the role of intracellular hemin in its mechanism of antimalarial action. PMID:15686911 biolink:Article|biolink:NamedThing|biolink:Publication 2005 Bioorg Med Chem Lett Syntheses and properties of the major hydroxy metabolites in humans of blonanserin AD-5423, a novel antipsychotic agent. PMID:15494035 biolink:Article|biolink:NamedThing|biolink:Publication 2004 Biochem Soc Trans Amylin receptors: molecular composition and pharmacology. PMID:15126366 biolink:Article|biolink:NamedThing|biolink:Publication 2004 Cancer Res Characterization of the interaction of ingenol 3-angelate with protein kinase C. PMID:2165421 biolink:Article|biolink:NamedThing|biolink:Publication 1990 Biochim Biophys Acta Flux-dependent increase in the stoichiometry of charge translocation by mitochondrial ATPase/ATP synthase induced by almitrine. PMID:23647933 biolink:Article|biolink:NamedThing|biolink:Publication 2013 J Cardiovasc Electrophysiol Dronedarone's inhibition of If current is the primary mechanism responsible for its bradycardic effect. PMID:24400777 biolink:Article|biolink:NamedThing|biolink:Publication 2014 J Med Chem Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A. PMID:22470110 biolink:Article|biolink:NamedThing|biolink:Publication 2012 Antimicrob Agents Chemother Pharmacokinetic/Pharmacodynamic predictors of clinical potency for hepatitis C virus nonnucleoside polymerase and protease inhibitors. PMID:24102143 biolink:Article|biolink:NamedThing|biolink:Publication 2014 Br J Pharmacol Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor. PMID:9347318 biolink:Article|biolink:NamedThing|biolink:Publication 1997 Gen Pharmacol Antagonistic effects of isofloxythepin on dopamine D1 and D2 receptors and behaviors in rats. PMID:24786236 biolink:Article|biolink:NamedThing|biolink:Publication 2014 Acta Pharmacol Sin Inhibitory effects of phytochemicals on metabolic capabilities of CYP2D6(*)1 and CYP2D6(*)10 using cell-based models in vitro. PMID:12388666 biolink:Article|biolink:NamedThing|biolink:Publication 2002 J Pharmacol Exp Ther Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. PMID:2907502 biolink:Article|biolink:NamedThing|biolink:Publication 1988 3 Nihon Yakurigaku Zasshi Pharmacological investigation of bezafibrate, a hypolipidemic agent. II. Mechanism of the hypolipidemic action of bezafibrate in rats 92 PMID:4396765 biolink:Article|biolink:NamedThing|biolink:Publication 1971 10 S Afr Med J A comparison of the effects of noradrenaline, adrenaline and some phenylephrine derivatives on alpha-, beta- and beta- adrenergic receptors 45 PMID:23859232 biolink:Article|biolink:NamedThing|biolink:Publication 2013 9 J Asthma A review on leukotrienes and their receptors with reference to asthma 50 PMID:23928358 biolink:Article|biolink:NamedThing|biolink:Publication 2013 40 J Biol Chem VKORC1L1, an enzyme rescuing the vitamin K 2,3-epoxide reductase activity in some extrahepatic tissues during anticoagulation therapy 288 PMID:17877367 biolink:Article|biolink:NamedThing|biolink:Publication 2007 40 Biochemistry Molecular identification of the human melanocortin-2 receptor responsible for ligand binding and signaling 46 PMID:23319593 biolink:Article|biolink:NamedThing|biolink:Publication 2013 9 J Biol Chem Hydralazine and organic nitrates restore impaired excitation-contraction coupling by reducing calcium leak associated with nitroso-redox imbalance 288 PMID:19466525 biolink:Article|biolink:NamedThing|biolink:Publication 2009 3 Heart Vessels Effect of edaravone, a novel free radical scavenger, supplemented to cardioplegia on myocardial function after cardioplegic arrest: in vitro study of isolated rat heart 24 http://professional.diabetes.org/Content/Posters/2008/p502-P.pdf biolink:InformationResource|biolink:NamedThing 2008 PMID:10427 biolink:Article|biolink:NamedThing|biolink:Publication Harms HH 1976 2 J Pharmacol Exp Ther Isoproterenol antagonism of cardioselective beta adrenergic receptor blocking agents: a comparative study of human and guinea-pig cardiac and bronchial beta adrenergic receptors 199 PMID:23393163 biolink:Article|biolink:NamedThing|biolink:Publication 2013 5 Mol Pharmacol Vesnarinone suppresses TNFalpha mRNA expression by inhibiting valosin-containing protein 83 PMID:8405122 biolink:Article|biolink:NamedThing|biolink:Publication 1993 1 Eur J Pharmacol Ca2+(-)dependent and Ca2+(-)independent vasorelaxation induced by cardiotonic phosphodiesterase inhibitors 240 PMID:15212190 biolink:Article|biolink:NamedThing|biolink:Publication 2004 5 Arzneimittelforschung Clinical evaluation of a transdermal therapeutic system of the beta2-agonist tulobuterol in patients with mild or moderate persistent bronchial asthma 54 http://eisai.jp/medical/products/di/EPI/COR_A_EPI.pdf biolink:NamedThing|biolink:Publication 2009 Coretec Injection 5 mg http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125557lbl.pdf biolink:NamedThing|biolink:Publication 2014 PMID:10364735 biolink:Article|biolink:NamedThing|biolink:Publication 1999 3 Respiration Reproterol: beta-2-agonist, theophylline, or both? 66 PMID:22037378 biolink:Article|biolink:NamedThing|biolink:Publication 2011 11 Nat Biotechnol Comprehensive analysis of kinase inhibitor selectivity 29 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212862s000lbl.pdf biolink:NamedThing|biolink:Publication 2019 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf biolink:NamedThing|biolink:Publication 2019 PMID:27003761 biolink:Article|biolink:NamedThing|biolink:Publication Menichincheri M, Ardini E, Magnaghi P, Avanzi N, Banfi P, Bossi R, Buffa L, Canevari G, Ceriani L, Colombo M, Corti L, Donati D, Fasolini M, Felder E, Fiorelli C, Fiorentini F, Galvani A, Isacchi A, Borgia AL, Marchionni C, Nesi M, Orrenius C, Panzeri A, Pesenti E, Rusconi L, Saccardo MB, Vanotti E, Perrone E, Orsini P 2016 7 J Med Chem Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor 59 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211675s000lbl.pdf biolink:NamedThing|biolink:Publication 2019 PMID:30886973 biolink:Article|biolink:NamedThing|biolink:Publication Parmentier JM, Voss J, Graff C, Schwartz A, Argiriadi M, Friedman M, Camp HS, Padley RJ, George JS, Hyland D, Rosebraugh M, Wishart N, Olson L, Long AJ 2018 23 BMC Rheumatology In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494) 2 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf biolink:NamedThing|biolink:Publication 2019 PMID:18394554 biolink:Article|biolink:NamedThing|biolink:Publication Wernig G, Kharas MG, Okabe R, Moore SA, Leeman DS, Cullen DE, Gozo M, McDowell EP, Levine RL, Doukas J, Mak CC, Noronha G, Martin M, Ko YD, Lee BH, Soll RM, Tefferi A, Hood JD, Gilliland DG 2008 4 Cancer Cell Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. 13 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210828s000lbl.pdf biolink:NamedThing|biolink:Publication 2019 PMID:28495802 biolink:Article|biolink:NamedThing|biolink:Publication Yin J, Tse CM, Cha B, Sarker R, Zhu XC, Walentinsson A, Greasley PJ, Donowitz M 2017 2 Am J Physiol Gastrointest Liver Physiol A common NHE3 single-nucleotide polymorphism has normal function and sensitivity to regulatory ligands 313 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211801s000lbl.pdf biolink:NamedThing|biolink:Publication 2019 PMID:29706423 biolink:Article|biolink:NamedThing|biolink:Publication Thoreau E, Arlabosse JM, Bouix-Peter C, Chambon S, Chantalat L, Daver S, Dumais L, Duvert G, Feret A, Ouvry G, Pascau J, Raffin C, Rodeville N, Soulet C, Tabet S, Talano S, Portal T 2018 10 Bioorg Med Chem Lett Structure-based design of Trifarotene (CD5789), a potent and selective RARγ agonist for the treatment of acne 28 PMID:20855361 biolink:Article|biolink:NamedThing|biolink:Publication Nelson DL, Phebus LA, Johnson KW, Wainscott DB, Cohen ML, Calligaro DO, Xu YC 2010 10 Cephalalgia Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan 30 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213217s000lbl.pdf biolink:NamedThing|biolink:Publication 2019 PMID:31381333 biolink:Article|biolink:NamedThing|biolink:Publication Guo Y, Liu Y, Hu N, Yu D, Zhou C, Shi G, Zhang B, Wei M, Liu J, Luo L, Tang Z, Song H, Guo Y, Liu X, Su D, Zhang S, Song X, Zhou X, Hong Y, Chen S, Cheng Z, Young S, Wei Q, Wang H, Wang Q, Lv L, Wang F,Xu H, Sun H, Xing H, Li N, Zhang W, Wang Z, Liu G, Sun Z, Zhou D, Li W, Liu L, Wang L, Wang Z 2019 17 J Med Chem Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase 62 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/0212194s000lbl.pdf biolink:NamedThing|biolink:Publication 2019 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213137s000lbl.pdf biolink:NamedThing|biolink:Publication 2019 PMID:27378309 biolink:Article|biolink:NamedThing|biolink:Publication Oksenberg D, Dufu K, Patel MP, Chuang C, Li Z, Xu Q, Silva-Garcia A, Zhou C, Hutchaleelaha A, Patskovska L, Patskovsky Y, Almo SC, Sinha U, Metcalf BW, Archer DR 2016 1 Br J Haematol GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease 175 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211970s000lbl.pdf biolink:NamedThing|biolink:Publication 2019 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209500s000lbl.pdf biolink:NamedThing|biolink:Publication 2019 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212028s000lbl.pdf biolink:NamedThing|biolink:Publication 2019 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211765s000lbl.pdf biolink:NamedThing|biolink:Publication 2019 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761062s000lbl.pdf biolink:NamedThing|biolink:Publication 2019 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761125s000lbl.pdf biolink:NamedThing|biolink:Publication 2019 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761136lbl.pdf biolink:NamedThing|biolink:Publication 2019 PMID:24658078 biolink:Article|biolink:NamedThing|biolink:Publication Suragani RN, Cadena SM, Cawley SM, Sako D, Mitchell D, Li R, Davies MV, Alexander MJ, Devine M, Loveday KS, Underwood KW, Grinberg AV, Quisel JD, Chopra R, Pearsall RS, Seehra J, Kumar R 2014 4 Nat Med Transforming growth factor-beta superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis 20 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761128s000lbl.pdf biolink:NamedThing|biolink:Publication 2019 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761137s000lbl.pdf biolink:NamedThing|biolink:Publication 2019 PMID:27013195 biolink:Article|biolink:NamedThing|biolink:Publication Challita-Eid PM, Satpayev D, Yang P, An Z, Morrison K, Shostak Y, Raitano A, Nadell R, Liu W, Lortie DR, Capo L, Verlinsky A, Leavitt M, Malik F, Avina H, Guevara CI, Dinh N, Karki S, Anand BS, Pereira DS, Joseph IB, Doñate F, Morrison K, Stover DR 2016 10 Cancer Res Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models 76 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761139s000lbl.pdf biolink:NamedThing|biolink:Publication 2019 PMID:27026201 biolink:Article|biolink:NamedThing|biolink:Publication Ogitani Y, Aida T, Hagihara K, Yamaguchi J, Ishii C, Harada N, Soma M, Okamoto H, Oitate M, Arakawa S, Hirai T, Atsumi R, Nakada T, Hayakawa I, Abe Y, Agatsuma T 2016 20 Clin Cancer Res DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1 22 https://www.ema.europa.eu/en/documents/product-information/nuceiva-epar-product-information_en.pdf biolink:NamedThing|biolink:Publication 2019 PMID:27412122 biolink:Article|biolink:NamedThing|biolink:Publication Markham A 2016 12 Drugs Atezolizumab: First Global Approval 76 PMID:30805897 biolink:Article|biolink:NamedThing|biolink:Publication Dhillon S 2019 5 Drugs Roxadustat: First Global Approval 79 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212273s000lbl.pdf biolink:NamedThing|biolink:Publication 2019 PMID:29856623 biolink:Article|biolink:NamedThing|biolink:Publication Wu Y, Jiang Z, Li Z, Gu J, You Q, Zhang X 2018 12 J Med Chem Click Chemistry-Based Discovery of [3-Hydroxy-5-(1 H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia 61 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211672s000,211673s000lbl.pdf biolink:NamedThing|biolink:Publication 2019 PMID:29061741 biolink:Article|biolink:NamedThing|biolink:Publication Ito A, Sato T, Ota M, Takemura M, Nishikawa T, Toba S, Kohira N, Miyagawa S, Ishibashi N, Matsumoto S, Nakamura R, Tsuji M, Yamano Y 2017 1 Antimicrob Agents Chemother In Vitro Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria 62 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209445s000lbl.pdf biolink:NamedThing|biolink:Publication 2019 https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206488lbl.pdf biolink:NamedThing|biolink:Publication 2019 PMID:8103915 biolink:Article|biolink:NamedThing|biolink:Publication Blasi J, Chapman ER, Link E, Binz T, Yamasaki S, De Camilli P, Sudhof TC, Niemann H, Jahn R 1993 6442 Nature Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25 365 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214103lbl.pdf biolink:NamedThing|biolink:Publication 2020 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761150Orig1s000MultidisciplineR.pdf biolink:NamedThing|biolink:Publication 2020 https://www.ema.europa.eu/en/documents/assessment-report/hepcludex-epar-public-assessment-report_en.pdf biolink:NamedThing|biolink:Publication 2020 https://www.pmda.go.jp/files/000237990.pdf biolink:NamedThing|biolink:Publication 2020 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206966lbl.pdf biolink:NamedThing|biolink:Publication 2020 PMID:8035423 biolink:Article|biolink:NamedThing|biolink:Publication Rosowsky A, Bader H, Wright JE, Keyomarsi K, Matherly LH 1994 14 J Med Chem Synthesis and biological activity of N omega-hemiphthaloyl-alpha,omega- diaminoalkanoic acid analogues of aminopterin and 3',5-dichloroaminopterin 37 PMID:21118657 biolink:Article|biolink:NamedThing|biolink:Publication Dean O, Giorlando F, Berk M 2011 2 J Psychiatry Neurosci N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action 36 https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/18603s19lbl.pdf biolink:NamedThing|biolink:Publication 1998 PMID:23832378 biolink:Article|biolink:NamedThing|biolink:Publication Fischer F, Vonderlin N, Zitron E, Seyler C, Scherer D, Becker R, Katus HA, Scholz EP 2013 11 Naunyn Schmiedebergs Arch Pharmacol Inhibition of cardiac Kv1.5 and Kv4.3 potassium channels by the class Ia anti-arrhythmic ajmaline: mode of action 386 https://www.ema.europa.eu/en/documents/mrl-report/albendazole-oxide-summary-report-2-committee-veterinary-medicinal-products_en.pdf biolink:NamedThing|biolink:Publication 1999 PMID:20167843 biolink:Article|biolink:NamedThing|biolink:Publication Doughty-Shenton D, Joseph JD, Zhang J, Pagliarini DJ, Kim Y, Lu D, Dixon JE, Casey PJ 2010 2 J Pharmacol Exp Ther Pharmacological targeting of the mitochondrial phosphatase PTPMT1 333 PMID:22981367 biolink:Article|biolink:NamedThing|biolink:Publication Skolnick P 2012 11 Trends Pharmacol Sci Anxioselective anxiolytics: on a quest for the Holy Grail 33 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214377s000lbl.pdf biolink:NamedThing|biolink:Publication 2021 PMID:28557445 biolink:Article|biolink:NamedThing|biolink:Publication Follmann M, Ackerstaff J, Redlich G, Wunder F, Lang D, Kern A, Fey P, Griebenow N, Kroh W, Becker-Pelster EM, Kretschmer A, Geiss V, Li V, Straub A, Mittendorf J, Jautelat R, Schirok H, Schlemmer KH, Lustig K, Gerisch M, Knorr A, Tinel H, Mondritzki T, Trubel H, Sandner P, Stasch JP 2017 12 J Med Chem Discovery of the soluble guanylate cyclase stimulator vericiguat (BAY 1021189) for the treatment of chronic heart failure 60 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212887s000lbl.pdf biolink:NamedThing|biolink:Publication 2021 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213176s000lbl.pdf biolink:NamedThing|biolink:Publication 2021 PMID:29475723 biolink:Article|biolink:NamedThing|biolink:Publication Burris HA 3rd, Flinn IW, Patel MR, Fenske TS, Deng C, Brander DM, Gutierrez M, Essell JH, Kuhn JG, Miskin HP, Sportelli P, Weiss MS, Vakkalanka S, Savona MR, O'Connor OA 2018 4 Lancet Oncol Umbralisib, a novel PI3Kdelta and casein kinase-1epsilon inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study 19 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214200s000lbl.pdf biolink:NamedThing|biolink:Publication 2021 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214200Orig1s000PharmR.pdf biolink:NamedThing|biolink:Publication 2021 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213026lbl.pdf biolink:NamedThing|biolink:Publication 2021 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214018s000lbl.pdf biolink:NamedThing|biolink:Publication 2021 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214383s000lbl.pdf biolink:NamedThing|biolink:Publication 2021 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213498s000lbl.pdf biolink:NamedThing|biolink:Publication 2021 PMID:20446681 biolink:Article|biolink:NamedThing|biolink:Publication Bolli MH, Abele S, Binkert C, Bravo R, Buchmann S, Bur D, Gatfield J, Hess P, Kohl C, Mangold C, Mathys B, Menyhart K, Muller C, Nayler O, Scherz M, Schmidt G, Sippel V, Steiner B, Strasser D, Treiber A, Weller T 2010 10 J Med Chem 2-Imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists 53 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214231s000lbl.pdf biolink:NamedThing|biolink:Publication 2021 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214231Orig1s000PharmR.pdf biolink:NamedThing|biolink:Publication 2021 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211964s000lbl.pdf biolink:NamedThing|biolink:Publication 2021 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/211964Orig1s000IntegratedR.pdf biolink:NamedThing|biolink:Publication 2021 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761181s000lbl.pdf biolink:NamedThing|biolink:Publication 2021 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214154s000lbl.pdf biolink:NamedThing|biolink:Publication 2021 PMID:18464023 biolink:Article|biolink:NamedThing|biolink:Publication Coelingh Bennink HJ, Holinka CF, Diczfalusy E 2008 1 Climacteric Estetrol review: profile and potential clinical applications 11 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761174s000lbl.pdf biolink:NamedThing|biolink:Publication 2021 PMID:32134960 biolink:Article|biolink:NamedThing|biolink:Publication Brown ME, Bedinger D, Lilov A, Rathanaswami P, Vásquez M, Durand S, Wallace-Moyer I, Zhong L, Nett JH, Burnina I, Caffry I, Lynaugh H, Sinclair M, Sun T, Bukowski J, Xu Y, Abdiche YN 2020 3 PLoS One Assessing the binding properties of the anti-PD-1 antibody landscape using label-free biosensors 15 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761196s000lbl.pdf biolink:NamedThing|biolink:Publication 2021 https://www.fda.gov/media/143603/download biolink:NamedThing|biolink:Publication 2021 https://www.fda.gov/media/145802/download biolink:NamedThing|biolink:Publication 2021 https://www.fda.gov/media/145611/download biolink:NamedThing|biolink:Publication 2021 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215014s000lbl.pdf biolink:NamedThing|biolink:Publication 2021 PMID:24497537 biolink:Article|biolink:NamedThing|biolink:Publication Risitano AM, Ricklin D, Huang Y, Reis ES, Chen H, Ricci P, Lin Z, Pascariello C, Raia M, Sica M, Del Vecchio L, Pane F, Lupu F, Notaro R, Resuello RR, DeAngelis RA, Lambris JD 2014 13 Blood Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria 123 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214793s000lbl.pdf biolink:NamedThing|biolink:Publication 2021 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214622s000lbl.pdf biolink:NamedThing|biolink:Publication 2021 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213378s000lbl.pdf biolink:NamedThing|biolink:Publication 2021 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214665s000lbl.pdf biolink:NamedThing|biolink:Publication 2021 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214900s000lbl.pdf biolink:NamedThing|biolink:Publication 2021 PMID:24323472 biolink:Article|biolink:NamedThing|biolink:Publication Jimenez-Ortigosa C, Paderu P, Motyl MR, Perlin DS 2014 2 Antimicrob Agents Chemother Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida Species and Aspergillus species isolates 58 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/761181Orig1s000PharmR.pdf biolink:NamedThing|biolink:Publication 2021